var title_f1_31_1520="Confounding";
var content_f1_31_1520=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F67729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F67729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    Confounding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Confounding occurs when a confounder is associated with the exposure and is a predictor of the outcome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_31_1520=[""].join("\n");
var outline_f1_31_1520=null;
var title_f1_31_1521="Sausage digit second toe";
var content_f1_31_1521=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F50959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F50959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sausage digit (left 2nd toe)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sausage like swelling of the left second toe is apparent in this photograph of a patient with reactive arthritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Henning Zeidler.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_31_1521=[""].join("\n");
var outline_f1_31_1521=null;
var title_f1_31_1522="Patient information: Roseola (The Basics)";
var content_f1_31_1522=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17204\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/26/8609\">",
"         Roseola rash",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?39/40/40578\">",
"         Patient information: Fever in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/21/36179\">",
"         Patient information: Giving your child over-the-counter medicines (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Roseola (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/roseola-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H6663291\">",
"      <span class=\"h1\">",
"       What is roseola?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Roseola is a common illness in children younger than 2 years. It causes a fever that lasts 3 to 5 days and then a rash. Roseola can be alarming to parents, because it can cause a high fever. But usually, the condition is not serious and goes away without treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6663306\">",
"      <span class=\"h1\">",
"       What are the symptoms of roseola?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptoms of roseola are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Might get as high as 104&deg;F (40&deg;C) or above",
"       </li>",
"       <li>",
"        Lasts 3 to 5 days &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Rash (",
"        <a class=\"graphic graphic_picture graphicRef76269 \" href=\"UTD.htm?8/26/8609\">",
"         picture 1",
"        </a>",
"        )",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Starts as the fever is going away",
"       </li>",
"       <li>",
"        Shows up first on the neck, chest, and belly, then spreads to the face, arms, and legs",
"       </li>",
"       <li>",
"        Is pinkish-red in color",
"       </li>",
"       <li>",
"        Normally does not itch",
"       </li>",
"       <li>",
"        Lasts for 1 to 2 days in most children, but might come and go within 2 to 4 hours",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Despite the fever and rash, most children with roseola do not seem sick. Still, some children have other symptoms such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Being tired",
"       </li>",
"       <li>",
"        Being fussy",
"       </li>",
"       <li>",
"        Not being hungry",
"       </li>",
"       <li>",
"        Swollen eyelids",
"       </li>",
"       <li>",
"        Swelling in the neck or behind the ears",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6663322\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to help my child?",
"      </span>",
"      &nbsp;&mdash;&nbsp;When your child has a fever you can do the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Offer him or her lots of fluids to drink. Call the doctor or nurse if your child won&rsquo;t or can&rsquo;t drink fluids for more than a few hours.",
"       </li>",
"       <li>",
"        Encourage your child to rest as much as he or she wants.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Medicines such as",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (sample brand name: Tylenol",
"      <sup>",
"       &reg;",
"      </sup>",
"      ) or",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (sample brand names: Advil",
"      <sup>",
"       &reg;",
"      </sup>",
"      , Motrin",
"      <sup>",
"       &reg;",
"      </sup>",
"      ) can help bring down a fever. But children don&rsquo;t usually need medicine for a fever unless they are uncomfortable. Check with your doctor or nurse about giving medicine for a fever.",
"     </p>",
"     <p>",
"      NEVER give your child",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"       aspirin",
"      </a>",
"      . Aspirin can cause a dangerous condition called Reye Syndrome in children.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6663337\">",
"      <span class=\"h1\">",
"       Should my child see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should take your child to see the doctor or nurse is he or she is:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Younger than 3 months and has a rectal temperature of 100.4&ordm;F (38&ordm;C) or higher. Any infant with a fever this high should see a doctor or nurse even if he or she looks normal or seems fine.",
"       </li>",
"       <li>",
"        Between 3 and 36 months and has a rectal temperature of 100.4&ordm;F (38&ordm;C) or higher for more than 3 days. Go right away of your child seems sick or is fussy, clingy, or refuses to drink fluids.",
"       </li>",
"       <li>",
"        Between 3 and 36 months old and has a rectal temperature of 102&ordm;F (38.9&ordm;C) or higher.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Children of any age should also see a doctor or nurse if they have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Oral, rectal, ear, or forehead temperature of 104&ordm;F (40&ordm;C) or higher",
"       </li>",
"       <li>",
"        Armpit temperature of 103&ordm;F (39.4&ordm;C) or higher",
"       </li>",
"       <li>",
"        A seizure caused by a fever",
"       </li>",
"       <li>",
"        Fevers that keep coming back, even if they last only a few hours",
"       </li>",
"       <li>",
"        A fever as well as an ongoing medical problem, such as heart disease, cancer, lupus, or sickle cell anemia",
"       </li>",
"       <li>",
"        A fever as well as a new skin rash",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6663352\">",
"      <span class=\"h1\">",
"       Will my child need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. The doctor or nurse will probably be able to tell if your child has roseola by learning about his or her symptoms and doing an exam.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6663367\">",
"      <span class=\"h1\">",
"       How is roseola treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is no treatment for roseola. The condition usually goes away on its own. But some children get medicines to bring down their fever.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6663382\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/40/40578?source=see_link\">",
"       Patient information: Fever in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=see_link\">",
"       Patient information: Giving your child over-the-counter medicines (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?1/31/1522?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17204 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-9A4DD99832-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_31_1522=[""].join("\n");
var outline_f1_31_1522=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6663291\">",
"      What is roseola?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6663306\">",
"      What are the symptoms of roseola?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6663322\">",
"      Is there anything I can do on my own to help my child?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6663337\">",
"      Should my child see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6663352\">",
"      Will my child need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6663367\">",
"      How is roseola treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6663382\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17204\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/26/8609\">",
"      Roseola rash",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/40/40578?source=related_link\">",
"      Patient information: Fever in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=related_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_31_1523="Patient information: Angioedema (The Basics)";
var content_f1_31_1523=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17000\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/55/32626\">",
"         Angioedema of the lips and tongue",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/41/7824\">",
"          Hives",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?32/30/33250\">",
"         Patient information: Anaphylaxis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/17/18706\">",
"         Patient information: Chronic hives (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/27/35250\">",
"         Patient information: Food allergy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/47/37617\">",
"         Patient information: Hives (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/51/15155\">",
"         Patient information: Insect bites and stings (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?21/37/22098\">",
"         Patient information: Allergy to penicillin and related antibiotics (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/57/15250\">",
"         Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/14/41186\">",
"         Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/47/29429\">",
"         Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/45/2772\">",
"         Patient information: Hives (urticaria) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/30/28134\">",
"         Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Angioedema (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/angioedema-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H10516232\">",
"      <span class=\"h1\">",
"       What is angioedema?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Angioedema is a condition that causes puffiness in the tissue under the skin. People with angioedema might have swelling of the face, eyelids, ears, mouth, tongue, hands, feet, or genitals (",
"      <a class=\"graphic graphic_picture graphicRef73131 \" href=\"UTD.htm?31/55/32626\">",
"       picture 1",
"      </a>",
"      ). &nbsp;",
"     </p>",
"     <p>",
"      Some people who get angioedema also get hives. Hives are red, raised patches of skin that are very itchy (",
"      <a class=\"graphic graphic_picture graphicRef79242 \" href=\"UTD.htm?7/41/7824\">",
"       picture 2",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Sometimes, people have symptoms of angioedema when they are having a dangerous allergic reaction.",
"      <strong>",
"       Call 9-1-1 for an ambulance",
"      </strong>",
"      if you suddenly have puffiness or hives",
"      <strong>",
"       plus any of the following",
"      </strong>",
"      :",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Trouble breathing",
"       </li>",
"       <li>",
"        Tightness in the throat",
"       </li>",
"       <li>",
"        Nausea and vomiting",
"       </li>",
"       <li>",
"        Cramps or stomach pain",
"       </li>",
"       <li>",
"        Passing out",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10516247\">",
"      <span class=\"h1\">",
"       Why did I get angioedema?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A common cause of angioedema is allergies. If you just got angioedema for the first time, it might be because you have a new allergy to something. Allergies to the following things can cause angioedema:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicines, such as antibiotics or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"       </li>",
"       <li>",
"        Something the person with angioedema touched, such as a plant, animal saliva, or latex",
"       </li>",
"       <li>",
"        Insect stings",
"       </li>",
"       <li>",
"        Foods, such as eggs, nuts, fish, or shellfish",
"       </li>",
"       <li>",
"        Exercise",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Also, certain medicines used to treat high blood pressure or heart disease can sometimes cause angioedema. But people who get angioedema because of medicines usually don&rsquo;t have hives or itching. Medicines that can cause angioedema include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Angiotensin-converting enzyme inhibitors (called &ldquo;ACE inhibitors&rdquo;) such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?29/31/30197?source=see_link\">",
"         enalapril",
"        </a>",
"        ,",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?24/49/25365?source=see_link\">",
"         captopril",
"        </a>",
"        , and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?9/32/9734?source=see_link\">",
"         lisinopril",
"        </a>",
"        .",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Over-the-counter medicines for pain and fever, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        ,",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Motrin&reg; or Advil&reg;) and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        &nbsp;(sample brand name: Aleve&reg;)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Sometimes, doctors don&rsquo;t know for sure what caused a person to get angioedema.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10516264\">",
"      <span class=\"h1\">",
"       Is there a test for angioedema?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No, there is not test. But your doctor or nurse should be able to tell if you have angioedema by learning about your symptoms and doing an exam. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10516279\">",
"      <span class=\"h1\">",
"       How is angioedema treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The treatment depends on how serious the symptoms are. If you get angioedema because of a dangerous allergic reaction, you will need to be treated in a hospital right away. At the hospital, the staff will give you treatments to stop the allergic reaction and help your symptoms.",
"     </p>",
"     <p>",
"      If your symptoms are mild, you might not need treatment. But you should try to figure out if anything triggered your symptoms. If so, you will need to avoid that trigger.",
"     </p>",
"     <p>",
"      Your doctor might recommend that you take medicines called antihistamines. These are the same medicines people take for seasonal allergies.",
"     </p>",
"     <p>",
"      Your doctor might also prescribe medicines called steroids. Steroids can help with itching and reduce swelling. But you should not take steroids for any longer than you need them, because they can cause serious side effects. These steroids are not the same ones that athletes take to build muscle.",
"     </p>",
"     <p>",
"      If you got angioedema because of a medicine you took, your doctor will switch you to a different medicine.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10516294\">",
"      <span class=\"h1\">",
"       Can angioedema be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can lower your chances of getting angioedema by avoiding foods, medicines, or insects that make you have an allergic reaction. If you get angioedema a lot, your doctor might recommend that you take antihistamines every day.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10516309\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/47/37617?source=see_link\">",
"       Patient information: Hives (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/30/33250?source=see_link\">",
"       Patient information: Anaphylaxis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/27/35250?source=see_link\">",
"       Patient information: Food allergy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/51/15155?source=see_link\">",
"       Patient information: Insect bites and stings (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/17/18706?source=see_link\">",
"       Patient information: Chronic hives (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/45/2772?source=see_link\">",
"       Patient information: Hives (urticaria) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/37/22098?source=see_link\">",
"       Patient information: Allergy to penicillin and related antibiotics (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=see_link\">",
"       Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/14/41186?source=see_link\">",
"       Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/30/28134?source=see_link\">",
"       Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/47/29429?source=see_link\">",
"       Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?1/31/1523?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17000 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-87E6A227E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_31_1523=[""].join("\n");
var outline_f1_31_1523=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10516232\">",
"      What is angioedema?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10516247\">",
"      Why did I get angioedema?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10516264\">",
"      Is there a test for angioedema?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10516279\">",
"      How is angioedema treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10516294\">",
"      Can angioedema be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10516309\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17000\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/55/32626\">",
"      Angioedema of the lips and tongue",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/41/7824\">",
"       Hives",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/37/22098?source=related_link\">",
"      Patient information: Allergy to penicillin and related antibiotics (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/30/33250?source=related_link\">",
"      Patient information: Anaphylaxis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=related_link\">",
"      Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/14/41186?source=related_link\">",
"      Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/17/18706?source=related_link\">",
"      Patient information: Chronic hives (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/27/35250?source=related_link\">",
"      Patient information: Food allergy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/47/29429?source=related_link\">",
"      Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/47/37617?source=related_link\">",
"      Patient information: Hives (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/45/2772?source=related_link\">",
"      Patient information: Hives (urticaria) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/51/15155?source=related_link\">",
"      Patient information: Insect bites and stings (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/30/28134?source=related_link\">",
"      Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_31_1524="Atopic dermatitis hand";
var content_f1_31_1524=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Atopic hand dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Atopic hand dermatitis typically involves the dorsum of hands. Diffuse erythema, scaling, and excoriations can be seen in this image.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_31_1524=[""].join("\n");
var outline_f1_31_1524=null;
var title_f1_31_1525="Carteolol (ophthalmic): Drug information";
var content_f1_31_1525=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Carteolol (ophthalmic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/42/10916?source=see_link\">",
"    see \"Carteolol (ophthalmic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8002015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Ophthalmic Agent, Antiglaucoma",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8001974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Glaucoma or intraocular hypertension: Ophthalmic: Instill 1 drop in affected eye(s) twice daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8001975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8002005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as hydrochloride [drops]: 1% (5 mL, 10 mL, 15 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8001928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8001976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Intended for twice daily dosing. Keep eye open and do not blink for 30 seconds after instillation. Wear sunglasses to avoid photophobic discomfort. Apply gentle pressure to lacrimal sac during and immediately following instillation (1 minute).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8001929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of chronic open-angle glaucoma and intraocular hypertension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8001927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Carteolol may be confused with carvedilol",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8001942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Ocular: Conjunctival hyperemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Ocular: Anisocoria, corneal punctate keratitis, corneal staining,  corneal sensitivity decreased, eye pain, vision disturbances",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8001932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to carteolol or any component of the formulation; sinus bradycardia; heart block greater than first-degree (except in patients with a functioning artificial pacemaker); cardiogenic shock; bronchial asthma, bronchospasm, or COPD; uncompensated cardiac failure; pulmonary edema",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8001939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; if used at all, should be used cautiously with close monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction abnormality: Consider pre-existing conditions such as sick sinus syndrome before initiating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use with caution in patients with compensated heart failure and monitor for a worsening of the condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral vascular disease (PVD): Use with caution in patients with PVD (including Raynaud's).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pheochromocytoma (untreated): Adequate alpha-blockade is required prior to use of any beta-blocker.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ophthalmic: Systemic absorption and adverse effects may occur, including bradycardia and/or hypotension. Should not be used alone in angle-closure glaucoma (has no effect on pupillary constriction).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8001965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8001966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9770116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9770115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal studies at maternally toxic doses.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9770117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8002007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Carteolol HCl Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (10 mL): $40.10",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8001978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intraocular pressure",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F14721644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Arteoptic (AT, BE, CH, CZ, HK, NL, PL, PT, SE, TH, TW);",
"     </li>",
"     <li>",
"      Arteoptic LA (ID);",
"     </li>",
"     <li>",
"      Calte (KP);",
"     </li>",
"     <li>",
"      Carteabak (FR);",
"     </li>",
"     <li>",
"      Cartens (AR);",
"     </li>",
"     <li>",
"      Carteof (PE);",
"     </li>",
"     <li>",
"      Carteol (BE, CZ, FR, IT, PK, TR);",
"     </li>",
"     <li>",
"      Carteol LP (FR);",
"     </li>",
"     <li>",
"      Catelol (TW);",
"     </li>",
"     <li>",
"      Catol (TW);",
"     </li>",
"     <li>",
"      Elebloc (TW);",
"     </li>",
"     <li>",
"      Endak (AT);",
"     </li>",
"     <li>",
"      Fortinol (GR);",
"     </li>",
"     <li>",
"      Glauteolol (AR);",
"     </li>",
"     <li>",
"      Karol (KP);",
"     </li>",
"     <li>",
"      Karteol (TW);",
"     </li>",
"     <li>",
"      Mikelan (BD, CL, JP, PH, SG, ZA);",
"     </li>",
"     <li>",
"      Mikelan LA (TW);",
"     </li>",
"     <li>",
"      Singlauc (AR);",
"     </li>",
"     <li>",
"      Teoptic (GB, IE, NL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8001970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks both beta",
"     <sub>",
"      1",
"     </sub>",
"     - and beta",
"     <sub>",
"      2",
"     </sub>",
"     -receptors and has mild intrinsic sympathomimetic activity; reduces intraocular pressure by decreasing aqueous humor production",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9042 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.76.133-59BD6D52C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_31_1525=[""].join("\n");
var outline_f1_31_1525=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002015\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8001974\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8001975\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002005\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8001928\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8001976\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8001929\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8001927\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8001942\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8001932\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8001939\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8001965\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8001966\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770116\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770115\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770117\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8002007\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8001978\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14721644\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8001970\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9042\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9042|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/42/10916?source=related_link\">",
"      Carteolol (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_31_1526="Diabetic muscle infarction";
var content_f1_31_1526=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diabetic muscle infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/31/1526/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/31/1526/contributors\">",
"     Lesley D Hordon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/31/1526/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/31/1526/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/31/1526/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/31/1526/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/31/1526/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/31/1526/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term diabetic muscle infarction is used to refer to spontaneous ischemic necrosis of skeletal muscle, unrelated to atheroembolism or occlusion of major arteries. Also referred to as spontaneous diabetic myonecrosis, it causes acute or subacute pain, swelling and tenderness, typically in the thigh or calf. The clinical manifestations, diagnosis, differential diagnosis, treatment, and prognosis of diabetic muscle infarction are discussed in this topic review.",
"   </p>",
"   <p>",
"    Diabetic muscle infarction is one of many micro- and macrovascular complications of diabetes. Others include diabetic retinopathy, nephropathy, neuropathy, and atherosclerotic vascular disease affecting other circulatory beds. An approach to minimizing the risk of complications arising from diabetic micro- and macrovascular disease is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link\">",
"     \"Overview of medical care in adults with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other musculoskeletal manifestations of diabetes mellitus and disorders with an increased prevalence in patients with diabetes are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22358?source=see_link\">",
"     \"Musculoskeletal complications in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous infarction of muscle is a rare condition which usually affects patients with longstanding and poorly controlled diabetes mellitus. It is more common in insulin dependent (Type I) diabetes and the majority of patients have multiple microvascular complications including retinopathy, nephropathy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1526/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. A systematic review of the literature through August 2001 identified a total of 116 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1526/abstract/3\">",
"     3",
"    </a>",
"    ]. The mean age at presentation was 43 (range 19 to 81 years), the average duration of diabetes was 14 years (range 0 to 50), and vascular complications of diabetes were present in the majority of cases, particularly nephropathy (71 percent), retinopathy (57 percent) and neuropathy (55 percent).",
"   </p>",
"   <p>",
"    The primary pathologic findings in muscle biopsies from affected patients are muscle necrosis and edema; occlusion of arterioles and capillaries by fibrin may also be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1526/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. The pathogenesis is uncertain. Hyperglycemia with or without insulin resistance has many potentially adverse effects on the arterial vasculature and may also affect platelets and the levels of coagulation and thrombolytic factors. These effects are discussed elsewhere in the context of their role in predisposing to coronary heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=see_link\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Affected patients present with the acute onset of painful swelling of the thigh, or less commonly the calf, that then evolves over days or weeks. There is no history of trauma. The swelling may be mildly to extremely tender, and the patient may have a mild fever [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1526/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Bilateral involvement occurs in nearly one-third of cases and recurrence at the same or different site(s) in nearly one-half [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1526/abstract/5\">",
"     5",
"    </a>",
"    ]. Rarely, the upper limb may be involved. Neck muscle (levator scapulae) involvement, later complicated by staphylococcal sepsis, has been described in an immunosuppressed diabetic transplant patient [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1526/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Laboratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;Creatinine kinase levels may be normal or increased, probably depending upon the stage of the condition when sampling is undertaken. A 2004 review of 116 reported cases noted CK elevation of more than 150",
"    <span class=\"nowrap\">",
"     U/L",
"    </span>",
"    in 20 of 47 patients (45 percent) in whom this enzyme activity was measured [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1526/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Imaging features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography and magnetic resonance imaging have been used to assess patients with diabetic muscle infarction. Magnetic resonance imaging with intravenous contrast enhancement appears to be the most useful diagnostic technique (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Diagnosis'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;A paucity of data exists concerning the results with ultrasonography. In one study, the presence of internal linear echogenic structures, the absence of a predominant anechoic area, and no evidence of internal motion or swirling fluid with transducer pressure could discriminate a diabetic muscle infarction from an abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1526/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     MR imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;MR imaging may show high intensity in the involved muscle (on T2-weighted sequences), as well as subcutaneous edema and subfascial fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1526/abstract/2,5,8\">",
"     2,5,8",
"    </a>",
"    ]. The loss of the normal fatty intramuscular septa, a relatively common finding, is optimally observed with T1 weighted images. The addition of gadolinium can distinguish nonenhancing infarcted muscle from surrounding inflammation or edema [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1526/abstract/9\">",
"     9",
"    </a>",
"    ]. However, administration of gadolinium-containing MRI contrast agents should be avoided in patients with moderately or severely impaired renal function (eg, estimated glomerular filtration rate &lt; 15-30",
"    <span class=\"nowrap\">",
"     mL/min).",
"    </span>",
"   </p>",
"   <p>",
"    If",
"    gadolinium-based imaging must be performed in a patient with moderate to severely impaired renal function, there may be a role for dialysis to reduce the risk of development of nephrogenic systemic fibrosis (NSF). Causes and approaches to prevention of NSF are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link&amp;anchor=H24#H24\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\", section on 'If gadolinium must be given'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Arteriography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arteriography, which is not generally performed for diagnostic purposes, may reveal atherosclerotic luminal narrowing [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1526/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Muscle biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted, muscle necrosis and edema are the primary pathologic findings, but occlusion of arterioles and capillaries by fibrin may also be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1526/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. Needle biopsy may provide diagnostic tissue and is less likely to exacerbate the disease or prolong recuperation than is excisional muscle biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1526/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Awareness of the syndrome and the presence of clinical features noted above usually suggest the diagnosis. Laboratory and imaging studies are aimed at excluding other disorders (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Differential diagnosis'",
"    </a>",
"    below). Muscle biopsy may be necessary for confirmation of the diagnosis.",
"   </p>",
"   <p>",
"    An inflammatory response to the muscle infarction may make differentiation from infection difficult. In the 2004 review cited above, leukocytosis was present in 21 of 60 cases in which the leukocyte count was reported (35 percent) and elevation of the erythrocyte sedimentation rate to more than 50",
"    <span class=\"nowrap\">",
"     mm/h",
"    </span>",
"    in 26 of 35 (74 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1526/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since MR imaging clearly identifies the location of muscle involvement, it may be useful to guide prebiopsy assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1526/abstract/8\">",
"     8",
"    </a>",
"    ]. For patients with longstanding diabetes, known microvascular complications, no fever and no leukocytosis, the finding on MRI of increased T2 signal, muscle enlargement, subcutaneous and subfascial edema may avoid muscle biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1526/abstract/5,9\">",
"     5,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest the following diagnostic testing in patients with suspected diabetic muscle infarction:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count and differential",
"     </li>",
"     <li>",
"      Prothrombin time and partial tissue thromboplastin time",
"     </li>",
"     <li>",
"      Blood cultures for aerobic and anaerobic bacteria",
"     </li>",
"     <li>",
"      Plain film radiograph to assess for gas in affected muscle",
"     </li>",
"     <li>",
"      Venous Doppler ultrasound with compression",
"     </li>",
"     <li>",
"      MR imaging of affected and contralateral limbs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with fever",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    leukocytosis, in whom muscle infection cannot be excluded on the basis of the tests above, we recommend CT guided core needle biopsy and examination of the tissue with Gram stain, culture, and routine histopathology.",
"   </p>",
"   <p>",
"    We suggest surgical exploration and excisional biopsy in patients in whom a rapidly progressive infection of muscle or fascia cannot be excluded, or in those with signs of sepsis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among other causes of acute muscle pain and tenderness, bacterial infections such as pyomyositis, spontaneous gangrenous myositis, nontraumatic clostridial myonecrosis, and necrotizing fasciitis must be excluded expeditiously. Ultrasonography used to exclude venous thrombosis may reveal intramuscular hematomas or muscle tears. Diabetic patients with end-stage renal disease may develop soft tissue infarction due to calciphylaxis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pyomyositis &mdash; There is an increased propensity to pyomyositis in patients with diabetes mellitus and large muscles of the thigh are a commonly involved site. Early pyomyositis may be difficult to distinguish from ischemic muscle necrosis, however, fever, leukocytosis, and a well defined intramuscular fluid collection is commonly noted at a more advanced stage of bacterial muscle infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32950?source=see_link\">",
"       \"Pyomyositis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Spontaneous gangrenous myositis &mdash; Spontaneous gangrenous myositis due to streptococcal infection, in contrast to pyomyositis due to S aureus, is characterized by gangrenous necrosis, not abscess formation, more systemic toxicity, and a much worse prognosis (80 to 100 percent mortality). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=see_link\">",
"       \"Necrotizing soft tissue infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Clostridial myonecrosis &mdash; The presence of gas in muscle is characteristic of nontraumatic clostridial myonecrosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12264?source=see_link&amp;anchor=H12#H12\">",
"       \"Clostridial myonecrosis\", section on 'Spontaneous gas gangrene'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Necrotizing fasciitis &mdash; Necrotizing fasciitis is a deep seated infection of the subcutaneous tissue that results in progressive destruction of fascia and fat. Necrotizing fasciitis should be considered in diabetic patients with cellulitis who also have systemic signs of infection such as tachycardia, leukocytosis, marked hyperglycemia, or acidosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=see_link&amp;anchor=H8#H8\">",
"       \"Necrotizing soft tissue infections\", section on 'Necrotizing fasciitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Venous thrombosis &mdash; Pain, swelling, and skin discoloration in the involved extremity are common symptoms of venous thrombosis and these may be accompanied by the presence of a palpable cord (reflecting a thrombosed vein), ipsilateral edema, warmth,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      superficial venous dilation. Noninvasive studies, particularly compression ultrasonography may distinguish venous thrombosis from muscle infarction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=see_link\">",
"       \"Diagnosis of suspected deep vein thrombosis of the lower extremity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intramuscular hematoma &mdash; Intramuscular bleeding due to low energy blunt trauma or in patients with a heritable or acquired coagulopathy causes pain, swelling, and muscle tenderness. A history of trauma, bleeding disorder, or use of an anticoagulant is suggestive. Ischemic pain may result from increased intramuscular pressure that can be determined by measuring intracompartmental pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?1/31/1526/abstract/12\">",
"       12",
"      </a>",
"      ]. Ultrasonography, CT, or MR imaging of the hematoma is usually diagnostic [",
"      <a class=\"abstract\" href=\"UTD.htm?1/31/1526/abstract/13,14\">",
"       13,14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Calciphylaxis &mdash; Calciphylaxis (calcific uremic arteriolopathy) is typically characterized by areas of ischemic necrosis that develop in the dermis, subcutaneous fat, and less often involve muscle. Typically seen in patients with end-stage renal disease, these ischemic changes lead to livedo reticularis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      violaceous, painful, plaque&ndash;like subcutaneous nodules on the trunk, buttocks or proximal extremity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15017?source=see_link\">",
"       \"Calciphylaxis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neoplasm &mdash; Enlarging benign and malignant neoplasms are unlikely to be confused with muscle infarction, but tumor infarction or hemorrhage may cause acute pain and increasing size [",
"      <a class=\"abstract\" href=\"UTD.htm?1/31/1526/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=see_link&amp;anchor=H12227065#H12227065\">",
"       \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Introduction'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal treatment of this diabetic muscle infarction is uncertain. An analysis of previously published patient outcomes by the type of treatment received, noted the following mean times to recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1526/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rest and analgesics &mdash; 8 weeks",
"     </li>",
"     <li>",
"      Antiplatelet agents",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      antiinflammatory drugs &mdash; 5.5 weeks",
"     </li>",
"     <li>",
"      Surgical excision &mdash; 13 weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Physiotherapy may cause worsening of the condition [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1526/abstract/1,15\">",
"     1,15",
"    </a>",
"    ]. Routine daily activity, while often painful, is not harmful [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1526/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest addition of low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for patients with diabetic muscle infarction who are not already receiving antiplatelet therapy and who have no contraindications to aspirin therapy.",
"   </p>",
"   <p>",
"    Although the use of nonsteroidal antiinflammatory drugs (NSAIDs) may speed recovery, the diabetic with muscle infarction is likely to have comorbidities",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diabetic complications which relatively contraindicate treatment with these agents, including: renal disease, hypertension, heart failure, ischemic heart disease, or use of anticoagulants. Risks of peptic ulcer disease or gastrointestinal hemorrhage should also be assessed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .) In patients without risk factors for renal impairment or bleeding, short term use of a NSAID such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    can be considered, but risks must be weighed against benefits.",
"   </p>",
"   <p>",
"    Concomitant use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and NSAIDs has the potential to cause adverse drug interactions. Among these are interference with the beneficial antiplatelet effect of aspirin and an increased risk of gastroduodenal damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=see_link\">",
"     \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who are at high risk for NSAID adverse effects are candidates for analgesics. Those with severe muscle pain may require use of narcotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic muscle infarction resolves spontaneously over a few weeks to months in most patients. A second episode, however, involving the contralateral side has frequently been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1526/abstract/1,2,5,15\">",
"     1,2,5,15",
"    </a>",
"    ]. The long-term outlook is poor, reflecting the underlying arteriopathy, with death from a major vascular event occurring within a few years in the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1526/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetic muscle infarction is a rare disorder that affects patients who have relatively longstanding diabetes, many of whom have other micro or macrovascular complications. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations include acute or subacute onset of muscle pain, swelling, and associated tenderness. The muscles of the thigh and calf are most commonly affected. Frequent but nonspecific laboratory findings include elevation of plasma CK enzyme activity, leukocytosis, and elevated ESR; each occurring in a substantial proportion of patients. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Laboratory'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Definitive diagnosis of diabetic muscle infarction requires biopsy of the affected area of muscle that demonstrates ischemic necrosis and excludes infection. A clinically based diagnosis of muscle infarction may be appropriately made for patients with compatible MRI findings (ie, increased T2 signal in affected muscle, fascia, and subcutaneous tissues) and without clinical or laboratory features favoring infection (eg, fever, leukocytosis). Plain film radiography and venous compression ultrasonography are indicated to exclude the presence of gas in the soft tissues and assess for deep venous thrombosis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend a CT guided cutting needle biopsy for patients with suspected muscle infarction who also have clinical or imaging features suggesting infection of muscle, fascia, or those in whom a malignant neoplasm cannot be excluded.",
"     </li>",
"     <li>",
"      We recommend surgical exploration and excisional biopsy in patients in whom a rapidly progressive infection of muscle or fascia cannot be excluded, or in those with signs of sepsis.",
"     </li>",
"     <li>",
"      We suggest using low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      to both treat diabetic muscle infarction (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above) and to prevent life threatening cardiovascular events in patients with diabetes mellitus (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       Clopidogrel",
"      </a>",
"      is an alternative antiplatelet agent for patients who are allergic to aspirin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link&amp;anchor=H11#H11\">",
"       \"Overview of medical care in adults with diabetes mellitus\", section on 'Aspirin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Whilst NSAIDs are reported to shorten recovery time, the majority of patients with diabetic muscle infarction may have relative or absolute contraindications to their use. Risks versus benefits of treatment with these drugs need to be considered on an individual basis.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1526/abstract/1\">",
"      Rocca PV, Alloway JA, Nashel DJ. Diabetic muscular infarction. Semin Arthritis Rheum 1993; 22:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1526/abstract/2\">",
"      Umpierrez GE, Stiles RG, Kleinbart J, et al. Diabetic muscle infarction. Am J Med 1996; 101:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1526/abstract/3\">",
"      Trujillo-Santos AJ. Diabetic muscle infarction: an underdiagnosed complication of long-standing diabetes. Diabetes Care 2003; 26:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1526/abstract/4\">",
"      Barohn RJ, Kissel JT. Case-of-the-month: painful thigh mass in a young woman: diabetic muscle infarction. Muscle Nerve 1992; 15:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1526/abstract/5\">",
"      Kapur S, Brunet JA, McKendry RJ. Diabetic muscle infarction: case report and review. J Rheumatol 2004; 31:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1526/abstract/6\">",
"      Salehi P, Stull MA, Martellotto J, et al. Case report: diabetic myonecrosis of the neck complicated by infection in an islet transplanted patient. J Diabetes Complications 2009; 23:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1526/abstract/7\">",
"      Delaney-Sathy LO, Fessell DP, Jacobson JA, Hayes CW. Sonography of diabetic muscle infarction with MR imaging, CT, and pathologic correlation. AJR Am J Roentgenol 2000; 174:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1526/abstract/8\">",
"      Jelinek JS, Murphey MD, Aboulafia AJ, et al. Muscle infarction in patients with diabetes mellitus: MR imaging findings. Radiology 1999; 211:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1526/abstract/9\">",
"      Grigoriadis E, Fam AG, Starok M, Ang LC. Skeletal muscle infarction in diabetes mellitus. J Rheumatol 2000; 27:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1526/abstract/10\">",
"      Angervall L, Stener B. Tumoriform focal muscular degeneration in two diabetic patients. Diabetologia 1965; 1:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1526/abstract/11\">",
"      Keller DR, Erpelding M, Grist T. Diabetic muscular infarction. Preventing morbidity by avoiding excisional biopsy. Arch Intern Med 1997; 157:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1526/abstract/12\">",
"      Klasson SC, Vander Schilden JL. Acute anterior thigh compartment syndrome complicating quadriceps hematoma. Two case reports and review of the literature. Orthop Rev 1990; 19:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1526/abstract/13\">",
"      McVerry BA, Voke J, Vicary FR, Dormandy KM. Ultrasonography in the management of haemophilia. Lancet 1977; 1:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1526/abstract/14\">",
"      Dooms GC, Fisher MR, Hricak H, Higgins CB. MR imaging of intramuscular hemorrhage. J Comput Assist Tomogr 1985; 9:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1526/abstract/15\">",
"      Chester CS, Banker BQ. Focal infarction of muscle in diabetics. Diabetes Care 1986; 9:623.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5135 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-564C5304BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_31_1526=[""].join("\n");
var outline_f1_31_1526=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Laboratory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Imaging features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - MR imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Arteriography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Muscle biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15017?source=related_link\">",
"      Calciphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=related_link\">",
"      Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12264?source=related_link\">",
"      Clostridial myonecrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=related_link\">",
"      Diagnosis of suspected deep vein thrombosis of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22358?source=related_link\">",
"      Musculoskeletal complications in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=related_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=related_link\">",
"      Nonselective NSAIDs: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=related_link\">",
"      Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32950?source=related_link\">",
"      Pyomyositis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_31_1527="Anatomy of the volar aspect of the wrist";
var content_f1_31_1527=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69097&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69097&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Anatomy of the volar aspect of the wrist",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 601px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_31_1527=[""].join("\n");
var outline_f1_31_1527=null;
var title_f1_31_1528="Valvular heart disease induced by drugs";
var content_f1_31_1528=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Valvular heart disease induced by drugs",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/31/1528/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/31/1528/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/31/1528/contributors\">",
"     Gerard P Aurigemma, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/31/1528/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/31/1528/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/31/1528/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/31/1528/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/31/1528/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Valvular abnormalities have been described in association with anorectic drugs and with ergot derivatives including drugs used for treatment or prophylaxis of migraine, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"     ergotamine",
"    </a>",
"    and methysergide, and drugs used in the treatment of Parkinson disease, particularly pergolide and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/1\">",
"     1",
"    </a>",
"    ]. Use of 3,4-methylenedioxymethamphetamine (MDMA, also known as ecstasy) may also induce valve disease. The common pathogenetic link is increased serotonin activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The echocardiographic and pathologic features of the valve disease seen in patients with drug-induced valvular disease are similar to those occurring in carcinoid heart valve disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12472?source=see_link\">",
"     \"Carcinoid heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The link between these two conditions appears to be serotonin, a neurotransmitter that is elevated in serum and plasma of most patients with carcinoid heart valve disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/3\">",
"     3",
"    </a>",
"    ]. As noted above, fenfluramine and dexfenfluramine augment serotonergic activity, while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/32/26118?source=see_link\">",
"     phentermine",
"    </a>",
"    may contribute to the fenfluramine valvulopathy by interfering with the pulmonary clearance of serotonin.",
"   </p>",
"   <p>",
"    Serotonin is also thought to play a role in the valve disease associated with ergot derivatives",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"     ergotamine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/4\">",
"     4",
"    </a>",
"    ], methysergide [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/5\">",
"     5",
"    </a>",
"    ] and the dopamine agonists pergolide and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. These drugs are structurally similar to serotonin and are thought to produce valve disease by stimulation of serotonin (5-HT 2B) receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/6,9,10\">",
"     6,9,10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Parkinson disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Serotonin stimulates fibroblast growth and fibrogenesis, which appear to underlie the valve disease seen in patients with carcinoid and anorectic drug-related heart valve disease. More direct evidence for a central role of serotonin comes from studies in animals:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a rat model in which daily serotonin injections were given for three months, valvular abnormalities (aortic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pulmonary regurgitation) developed in six of ten rats, with histopathologic examination showed carcinoid-like plaques similar to those seen in humans with carcinoid heart disease [",
"      <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/11\">",
"       11",
"      </a>",
"      ]. There were no valvular changes in control rats.",
"     </li>",
"     <li>",
"      Another mechanism of raising serotonin levels is to interfere with its metabolism. This process is mediated in part by the 5-hydroxytryptamine (5-HT) transporter, which is responsible for serotonin inactivation as it passes through the lungs. Both valvular hyperplasia and fibrosis were noted in a mouse model in which the 5-HT transporter gene was knocked out [",
"      <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One concern with a central role for serotonin in the valvular heart disease associated with anorectic drugs has been that selective serotonin reuptake inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    ), which are commonly used for the treatment of depression and other disorders, do not appear do not appear to be associated with valve disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is possible that drug-induced activation of serotonin-2B receptors, which is located on both mitral and aortic valves, plays an important role. Support for this hypothesis comes from a study which found that medications associated with valvular heart disease, including fenfluramine, dexfenfluramine, methysergide, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"     ergotamine",
"    </a>",
"    , had high affinity for and were partial to full agonists of the serotonin-2B receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/9\">",
"     9",
"    </a>",
"    ]. In contrast, drugs not associated with valvular disease (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/32/26118?source=see_link\">",
"     phentermine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"     buspirone",
"    </a>",
"    ) had low affinity for and lacked agonist effects at this receptor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANORECTIC DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The consequences of obesity include a variety of disorders including cardiopulmonary diseases with morbid outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=see_link\">",
"     \"Health hazards associated with obesity in adults\"",
"    </a>",
"    .) As a result, some physicians have developed aggressive attitudes and strategies for weight reduction in obese patients. One such strategy is the prescription of appetite suppressing or anorectic drugs, usually in combination with diet, exercise, and behavior modification. Some of these drugs have been implicated in the pathogenesis of an unusual form of valvular heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who developed valve disease have generally been treated with fenfluramine in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/32/26118?source=see_link\">",
"     phentermine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=see_link\">",
"     \"Drug therapy of obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fenfluramine &mdash; Fenfluramine (Pondimin) is a sympathomimetic amine that promotes the release of serotonin and blocks its neuronal uptake. The ensuing increase in serotonergic activity has an anorectic effect. Fenfluramine was originally approved by the Food and Drug Administration (FDA) in 1973 for single-drug, short term use as an appetite suppressant.",
"     </li>",
"     <li>",
"      Dexfenfluramine &mdash; Dexfenfluramine (Redux) is the dextroisomer of fenfluramine. Its activity is relatively selective to serotonergic pathways in the brain, but the appetite suppression is similar to that of fenfluramine. In 1996, the FDA approved dexfenfluramine as a single-drug appetite suppressant for longer term use in markedly obese subjects.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/32/26118?source=see_link\">",
"       Phentermine",
"      </a>",
"      &mdash; Phentermine (Adipex, Fastin, Ionamin) is a noradrenergic central nervous system stimulant that was approved by the FDA as an appetite suppressant in 1959. When given alone, this agent has",
"      <strong>",
"       not",
"      </strong>",
"      been implicated in the pathogenesis of valvular heart disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Combinations of fenfluramine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/32/26118?source=see_link\">",
"     phentermine",
"    </a>",
"    (called",
"    <span class=\"nowrap\">",
"     fen/phen)",
"    </span>",
"    have been used with the hope that weight reduction might be achieved with lower doses and fewer side effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=see_link\">",
"     \"Drug therapy of obesity\"",
"    </a>",
"    .) Most of the reported cases of valvular disease in patients taking anorectic drugs were in patients using this combination [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 18 million prescriptions were written for either fenfluramine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/32/26118?source=see_link\">",
"     phentermine",
"    </a>",
"    in 1996 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/17\">",
"     17",
"    </a>",
"    ]. In 1997 the FDA asked the manufacturers to withdraw fenfluramine and dexfenfluramine (but not phentermine) from the market. Assuming that the average prescription was written for one month and that the treatment course lasted three to twelve months, it is likely that several million Americans have been exposed to these drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Relation to valvular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1997, cardiac ultrasonographers at the MeritCare Medical Center in Fargo, North Dakota and clinicians at the Mayo Clinic in Rochester, Minnesota described valvular heart disease in 24 women (average age 44) who had been treated with the combination of fenfluramine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/32/26118?source=see_link\">",
"     phentermine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/15\">",
"     15",
"    </a>",
"    ]. All 24 had cardiac symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a heart murmur. Aortic or mitral regurgitation (or both) was present in all 24; one-half also had tricuspid involvement. The average dose of fenfluramine was 60",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and the dose of phentermine was 30",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    The mean duration of treatment with fenfluramine-phentermine was 11 months (range 1 to 28 months). Five patients required valve replacement, while less severe valvular regurgitation was present in the remaining patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An additional 28 cases were reported simultaneously by physicians from the Food and Drug Administration (FDA) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/16\">",
"     16",
"    </a>",
"    ]. These patients, all women, exhibited a similar history of valvular heart disease in association with the use of a combination of fenfluramine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/32/26118?source=see_link\">",
"     phentermine",
"    </a>",
"    . As a result of these observations, the manufacturer withdrew fenfluramine and dexfenfluramine from the market (September, 1997).",
"   </p>",
"   <p>",
"    Subsequently, more than 100 additional provider-initiated case reports were received by the FDA. Valvulopathy was associated with the use of fenfluramine or dexfenfluramine, alone or in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/32/26118?source=see_link\">",
"     phentermine",
"    </a>",
"    . There were no cases with the use of phentermine alone.",
"   </p>",
"   <p>",
"    Unfortunately, these initial descriptions of an association between valvulopathy and anorectic drugs do not represent epidemiologic or even case-control studies. Subsequent randomized and case-controlled studies provided additional information [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/18-20\">",
"     18-20",
"    </a>",
"    ], but several issues remain unclear:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of regurgitant valvular lesions in obese patients not exposed to these drugs is not well-established. The patients in these reports did not routinely have echocardiography prior to drug therapy and it is therefore unclear how many may have had preexistent valvular abnormalities.",
"     </li>",
"     <li>",
"      The relative risks of fenfluramine and dexfenfluramine, alone or in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/32/26118?source=see_link\">",
"       phentermine",
"      </a>",
"      , as well as the effects of dose and duration of exposure are not well defined.",
"     </li>",
"     <li>",
"      The risk factors for valvulopathy have not been defined. Baseline body weight, concomitant medications, and other demographic factors must be assessed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A nonrandomized study compared the echocardiographic findings of 257 patients using any anorectic drugs with 239 control patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/19\">",
"     19",
"    </a>",
"    ]. Mild or greater aortic regurgitation or moderate or greater mitral regurgitation were present in 1.3 percent of controls, 12.8 percent of patients receiving dexfenfluramine (odds ratio 12.7), 22.8 percent of those taking the combination of dexfenfluramine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/32/26118?source=see_link\">",
"     phentermine",
"    </a>",
"    (odds ratio 24.5), and 25.2 percent of patients taking both fenfluramine and phentermine (odds ratio 26.3) (",
"    <a class=\"graphic graphic_figure graphicRef76203 \" href=\"UTD.htm?21/10/21677\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A much lower prevalence of valvulopathy has been reported by others. One nonrandomized study examined 223 patients exposed to dexfenfluramine for a mean of 6.9 months and 189 unexposed controls; at least mild aortic regurgitation or moderate mitral regurgitation was significantly more frequent in patients treated with dexfenfluramine (7.6 versus 2.1 percent for controls) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/21\">",
"     21",
"    </a>",
"    ]. The difference was primarily due to more frequent mild aortic regurgitation (6.3 versus 1.6 percent) (",
"    <a class=\"graphic graphic_figure graphicRef57538 \" href=\"UTD.htm?0/19/318\">",
"     figure 2",
"    </a>",
"    ). Factors independently associated with any grade of aortic regurgitation were older age, diastolic blood pressure greater than 95 mmHg (",
"    <a class=\"graphic graphic_figure graphicRef67953 \" href=\"UTD.htm?30/27/31165\">",
"     figure 3",
"    </a>",
"    ), and a shorter time from drug discontinuation to echocardiogram, which suggests that dexfenfluramine-related valve regurgitation may regress after drug discontinuation.",
"   </p>",
"   <p>",
"    Another nonrandomized, but reader-blinded, controlled echocardiographic study of 934 patients treated for at least 30 days with dexfenfluramine or",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/32/26118?source=see_link\">",
"      phentermine",
"     </a>",
"     /fenfluramine",
"    </span>",
"    and 539 untreated matched controls found an increase in the prevalence of aortic regurgitation with these drugs (8.9 and 13.7 versus 4.1 percent for placebo) but no difference in the prevalence of mitral regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/22\">",
"     22",
"    </a>",
"    ]. There was no difference in the rate of serious cardiac events (myocardial infarction, heart failure, or ventricular arrhythmia) in treated and untreated subjects.",
"   </p>",
"   <p>",
"    In a prospective randomized trial of dexfenfluramine or sustained-release dexfenfluramine versus placebo administered for an average of 71 days, echocardiograms were obtained in 1072 patients within one month of treatment discontinuation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/18\">",
"     18",
"    </a>",
"    ]. There was a nonsignificant trend towards more valvular regurgitation with dexfenfluramine compared to placebo (6.5 and 7.3 versus 4.5 percent, respectively). The low incidence of valvulopathy in this report may have been due to the brief duration of therapy; the course of the valvular disease in these patients is discussed below (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Course'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Support for a relationship between the duration of therapy and the incidence of valvular abnormalities comes from the Boston Collaborative Drug Surveillance Program which conducted a population-based and a nested case-control analysis of 6532 subjects treated with dexfenfluramine, 2371 who received fenfluramine, 862 treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/32/26118?source=see_link\">",
"     phentermine",
"    </a>",
"    , and 9281 obese subjects who did not take these drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/20\">",
"     20",
"    </a>",
"    ]. The five year cumulative incidence of an idiopathic valvular disorder was:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      0 per 10,000 among subjects who had not taken appetite suppressants or those who had taken",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/32/26118?source=see_link\">",
"       phentermine",
"      </a>",
"      alone",
"     </li>",
"     <li>",
"      7.1 per 10,000 among those treated with fenfluramine or dexfenfluramine for less than four months",
"     </li>",
"     <li>",
"      35 per 10,000 among patients treated with fenfluramine or dexfenfluramine for four or more months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another report of 226 obese patients followed prospectively for up to 30 months found significant, but not severe, aortic regurgitation in 6.6 percent and mitral regurgitation in 1.3 percent; there was no association with the dose administered or duration of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/23\">",
"     23",
"    </a>",
"    ]. The prevalence of valvular regurgitation in this study was comparable to what has been found in the general population in the Framingham Heart Study [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gross pathologic features included thickening of the mitral leaflets and chordae, with a glistening white appearance. The histopathologic picture is one of intact leaflet architecture with a plaque-like encasement of the leaflets; proliferative myofibroblasts are surrounded by an abundant extracellular matrix [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2003 guidelines from the American College of Cardiology, the American Heart Association, and the American Society of Echocardiography",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ASE)",
"    </span>",
"    recommended echocardiography to assess valve morphology and regurgitation in patients with a history of use of anorectic drugs or any other drug known to be associated with valvular heart disease, particularly those who are symptomatic, have cardiac murmurs, or have a technically inadequate auscultatory examination [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/26\">",
"     26",
"    </a>",
"    ]. Routine screening of all patients who have taken anorectic drugs was not recommended.",
"   </p>",
"   <p>",
"    The echocardiographic features of the valvulopathy are similar to those seen in some patients with rheumatic heart disease, but valve obstruction is conspicuously absent. The most common mitral valve findings include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thickening and diastolic doming of the anterior mitral leaflets with relative immobility of the posterior leaflets",
"     </li>",
"     <li>",
"      Prominent subvalvular disease with thickening and shortening of the chordae tendinae",
"     </li>",
"     <li>",
"      Leaflet tethering and malcoaptation contribute to the mitral regurgitation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The aortic valves appear thickened with leaflet retraction, although aortic regurgitation can occur in the presence of echocardiographically normal leaflets.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     FDA case definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor degrees of regurgitation (trace or mild mitral regurgitation or trace aortic regurgitation) are somewhat common in the general population and may occur without valvular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/27\">",
"     27",
"    </a>",
"    ]. Therefore, these lesser degrees of regurgitation were excluded from the 1997 FDA case definition of fenfluramine or dexfenfluramine-associated valvulopathy. The FDA case definition requires documented mild or greater aortic regurgitation OR moderate or greater mitral regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although not included in the FDA case definition, rates of significant (greater than mild) tricuspid regurgitation may approach those for significant mitral regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Tricuspid leaflets may be thickened with restricted mobility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography has been used to evaluate the course of valvular heart disease associated with anorectic drugs. The valvular lesions tend to be stable or improve in the great majority of patients after the cessation of these drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/31-34\">",
"     31-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of the trials described above randomly assigned over 1000 patients to dexfenfluramine, sustained-release dexfenfluramine, or placebo for an average of only 71 days [",
"      <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/18\">",
"       18",
"      </a>",
"      ]. Echocardiograms were obtained one month and one year after discontinuation in 914 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/31\">",
"       31",
"      </a>",
"      ]. The major finding was regression of aortic regurgitation but not mitral regurgitation in many treated patients with these lesions. The development or progression of valvular disease was unlikely after the cessation of therapy as the frequency of these changes was low and similar to that in the placebo group.",
"     </li>",
"     <li>",
"      Similar findings were noted in a second report of 50 patients with previous exposure to fenfluramines who had at least mild mitral (76 percent)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      aortic regurgitation (86 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/33\">",
"       33",
"      </a>",
"      ]. An initial echocardiogram was obtained a mean of 190 days after drug cessation and repeat echocardiography performed approximately one year later. Among the 38 patients with mitral regurgitation, 17 improved, 19 experienced no change, and 2 worsened by at least one grade. Among the 43 patients with aortic regurgitation, 19 improved, 22 were stable, and two worsened by at least one grade. The authors concluded that the potential for stabilization or improvement must be considered when counseling patients about the possible need for eventual valve replacement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ERGOT DERIVATIVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Valve disease has resulted from use of ergot derivatives in the treatment of migraine, Parkinson disease, and, less commonly, in the treatment of hyperprolactinemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ergot derivatives",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"     ergotamine",
"    </a>",
"    and methysergide have limited utility for treatment and prophylaxis of migraines largely due to their adverse effects which include induction of valvular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/4,5,35-39\">",
"     4,5,35-39",
"    </a>",
"    ]. Although most reported cases of valve disease have been asymptomatic, some patients have developed symptoms and required valve replacement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21194?source=see_link\">",
"     \"Acute treatment of migraine in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link\">",
"     \"Preventive treatment of migraine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Parkinson disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with ergot-derived dopamine agonists pergolide or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    , primarily for Parkinson disease, is associated with a clinically and statistically significant risk of valvular heart disease, with lesions similar to those associated with carcinoid, fenfluramine-induced, and other ergot-induced valvular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/6-8,40-44\">",
"     6-8,40-44",
"    </a>",
"    ]. The risk of valvular disease appears to increase relative to the cumulative dose of pergolide or cabergoline. As with anorectic drugs, the mechanism is probably related to pergolide and cabergoline activation of serotonin (5-HT 2B type) receptors expressed on heart valves, which in turn leads to valvular overgrowth [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a nested case-control study from the United Kingdom involving a cohort of 11,417 patients taking antiparkinsonian drugs, 31 patients with newly diagnosed cardiac valve regurgitation were compared with 664 controls; six were taking pergolide and six were taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/7\">",
"       7",
"      </a>",
"      ]. The risk of cardiac valve regurgitation was significantly increased with current use of pergolide (incidence-rate ratio [IRR] 7.1, 95% CI 2.3-22.3) and cabergoline (IRR 4.9, 95% CI 1.5-15.6) but not with other dopamine agonists. The risk of cardiac valve regurgitation was increased only for patients taking pergolide or cabergoline for six months or longer, and was particularly increased for both medications at doses higher than 3 mg daily.",
"     </li>",
"     <li>",
"      In a case-control study from Italy involving 155 patients taking dopamine agonists for Parkinson disease and 90 control subjects, the frequency of clinically important valve regurgitation determined by echocardiography was significantly higher in patients taking pergolide or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"       cabergoline",
"      </a>",
"      compared with controls (23.4 and 28.6 versus 5.6 percent, respectively) but not in those taking nonergot dopamine agonists (0 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, pergolide and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    should",
"    <strong>",
"     NOT",
"    </strong>",
"    be used as treatment for Parkinson disease. In the United States, pergolide was voluntarily withdrawn from the market in March 2007 due to the potential risk of heart valve damage [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hyperprolactinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"     Cabergoline",
"    </a>",
"    associated valvular disease has only rarely been reported in patients treated for hyperprolactinemia. In the United Kingdom study cited above, for example, only one of the 31 patients with valve disease were being treated for hyperprolactinemia compared to 29 for Parkinson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/7\">",
"     7",
"    </a>",
"    ]. This difference is at least in part dose-dependent. As noted above, the risk of valve disease is particularly increased at doses higher than 3",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/7\">",
"     7",
"    </a>",
"    ]; in comparison, the recommended cabergoline dose for hyperprolactinemia is only 0.5 to 2 mg per week. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"     \"Cabergoline: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MDMA (ECSTASY)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest that use of 3,4-Methylenedioxymethamphetamine (MDMA; known as ecstasy) may cause valve disease. An in vitro study found that MDMA and its N-demethylated metabolite 3,4-methylenedioxyamphetamine activated the 5-hydroxytryptamine 2B (5-HT2B) serotonin receptor and elicited a prolonged mitogenic response in human valvular interstitial cells similar to that induced by fenfluramine [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A preliminary report of 29 current or former users of MDMA and 29 gender- and age-matched controls found that 8 of 29 MDMA users had abnormal echocardiographic results (using the FDA case definition for valvulopathy due to appetite suppressant drugs (see above) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/28\">",
"     28",
"    </a>",
"    ]), compared to none in the control group [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/47\">",
"     47",
"    </a>",
"    ]. Among MDMA users, 13 had greater than mild tricuspid regurgitation and six had valvular strands; neither of these findings was present in any of the control subjects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial recommendations from the Centers for Disease Control and Prevention, Food and Drug Administration, and National Institutes of Health were issued in 1997 for patients who have been exposed to fenfluramine or dexfenfluramine for any length of time [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/28\">",
"     28",
"    </a>",
"    ]. More definitive recommendations were made by the 2003",
"    <span class=\"nowrap\">",
"     ACC/AHA/ASE",
"    </span>",
"    guidelines on echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anorectic drug (fenfluramine and dexfenfluramine) use should be discontinued. Caution is advised regarding the use of nonprescription anorectic drugs, herbal anorectics, and even diet supplements. The use of some ergot derivatives has also been shown to be associated with a valvulopathy.",
"     </li>",
"     <li>",
"      A cardiac history and physical examination, emphasizing cardiac auscultation, is indicated in all exposed patients. In the absence of abnormal findings, a repeat examination can be performed in six to eight months. The validity of this approach was illustrated in a study of 223 patients receiving dexfenfluramine for seven months; the absence of heart murmurs predicted the absence of echocardiographic valvular regurgitation in 93 percent of patients, while the presence of a murmur had a positive predictive value of only 19 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?1/31/1528/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Echocardiography is indicated in exposed patients with a heart murmur, symptoms of valvular heart disease, or physical characteristics or body habitus that preclude adequate cardiac auscultation.",
"     </li>",
"     <li>",
"      The optimal timing of follow-up echocardiography to determine the progression, regression, or stabilization of valvular lesions is not known. Depending upon the severity of the lesion, it is reasonable to perform follow-up studies at 6 to 12 months. Routine repetition of echocardiography was not recommended with previously normal studies or known trivial valvular abnormalities.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/1\">",
"      Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J. Drug-induced fibrotic valvular heart disease. Lancet 2009; 374:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/2\">",
"      Pellikka PA, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 1993; 87:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/3\">",
"      Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995; 92:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/4\">",
"      Hendrikx M, Van Dorpe J, Flameng W, Daenen W. Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature. J Heart Valve Dis 1996; 5:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/5\">",
"      Bana DS, MacNeal PS, LeCompte PM, et al. Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. Am Heart J 1974; 88:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/6\">",
"      Waller EA, Kaplan J, Heckman MG. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2005; 80:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/7\">",
"      Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/8\">",
"      Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007; 356:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/9\">",
"      Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000; 102:2836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/10\">",
"      Roth BL. Drugs and valvular heart disease. N Engl J Med 2007; 356:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/11\">",
"      Gustafsson BI, T&oslash;mmer&aring;s K, Nordrum I, et al. Long-term serotonin administration induces heart valve disease in rats. Circulation 2005; 111:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/12\">",
"      Mekontso-Dessap A, Brouri F, Pascal O, et al. Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation 2006; 113:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/13\">",
"      Mast ST, Gersing KR, Anstrom KJ, et al. Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation. Am J Cardiol 2001; 87:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/14\">",
"      Rosenbaum M, Leibel RL, Hirsch J. Obesity. N Engl J Med 1997; 337:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/15\">",
"      Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/16\">",
"      Graham DJ, Green L. Further cases of valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997; 337:635.",
"     </a>",
"    </li>",
"    <li>",
"     Langreth R. Critics claim diet clinics misuse obesity drugs. Wall Street Journal. March 31, 1997;B8.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/18\">",
"      Weissman NJ, Tighe JF Jr, Gottdiener JS, Gwynne JT. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. N Engl J Med 1998; 339:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/19\">",
"      Khan MA, Herzog CA, St Peter JV, et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 1998; 339:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/20\">",
"      Jick H, Vasilakis C, Weinrauch LA, et al. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998; 339:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/21\">",
"      Shively BK, Roldan CA, Gill EA, et al. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation 1999; 100:2161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/22\">",
"      Gardin JM, Schumacher D, Constantine G, et al. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000; 283:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/23\">",
"      Burger AJ, Sherman HB, Charlamb MJ, et al. Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. J Am Coll Cardiol 1999; 34:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/24\">",
"      Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 1999; 83:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/25\">",
"      Caccitolo JA, Connolly HM, Rubenson DS, et al. Operation for anorexigen-associated valvular heart disease. J Thorac Cardiovasc Surg 2001; 122:656.",
"     </a>",
"    </li>",
"    <li>",
"     Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline for the clinical application of echocardiography www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/27\">",
"      Klein AL, Burstow DJ, Tajik AJ, et al. Age-related prevalence of valvular regurgitation in normal subjects: a comprehensive color flow examination of 118 volunteers. J Am Soc Echocardiogr 1990; 3:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/28\">",
"      Centers for Disease Control and Prevention (CDC). Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb Mortal Wkly Rep 1997; 46:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/29\">",
"      Teramae CY, Connolly HM, Grogan M, Miller FA Jr. Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience. Mayo Clin Proc 2000; 75:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/30\">",
"      Dahl CF, Allen MR, Urie PM, Hopkins PN. Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals. BMC Med 2008; 6:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/31\">",
"      Weissman NJ, Panza JA, Tighe JF, Gwynne JT. Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/32\">",
"      Gardin JM, Weissman NJ, Leung C, et al. Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine. JAMA 2001; 286:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/33\">",
"      Mast ST, Jollis JG, Ryan T, et al. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography. Ann Intern Med 2001; 134:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/34\">",
"      Klein AL, Griffin BP, Grimm RA, et al. Natural history of valvular regurgitation using side-by-side echocardiographic analysis in anorexigen-treated subjects. Am J Cardiol 2005; 96:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/35\">",
"      Graham JR. Cardiac and pulmonary fibrosis during methysergide therapy for headache. Am J Med Sci 1967; 254:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/36\">",
"      Misch KA. Development of heart valve lesions during methysergide therapy. Br Med J 1974; 2:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/37\">",
"      Redfield MM, Nicholson WJ, Edwards WD, Tajik AJ. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 1992; 117:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/38\">",
"      Wilke A, Hesse H, Hufnagel G, Maisch B. Mitral, aortic and tricuspid valvular heart disease associated with ergotamine therapy for migraine. Eur Heart J 1997; 18:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/39\">",
"      Mart&iacute;nez Quintana E, Llorens Le&oacute;n R, Redondo Mart&iacute;nez E, et al. [Valvular heart disease associated with ergotamine]. Rev Esp Cardiol 2005; 58:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/40\">",
"      Flowers CM, Racoosin JA, Lu SL, Beitz JG. The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 2003; 78:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/41\">",
"      Pritchett AM, Morrison JF, Edwards WD, et al. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002; 77:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/42\">",
"      Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/43\">",
"      Baseman DG, O'Suilleabhain PE, Reimold SC, et al. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 2004; 63:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/44\">",
"      Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007; 6:826.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. FDA announces voluntary withdrawal of pergolide products (March 29, 2007). file://www.fda.gov/newsevents/newsroom/pressannouncements/2007/ucm108877.htm (Accessed on August 01, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/46\">",
"      Setola V, Hufeisen SJ, Grande-Allen KJ, et al. 3,4-methylenedioxymethamphetamine (MDMA, \"Ecstasy\") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 2003; 63:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/47\">",
"      Droogmans S, Cosyns B, D'haenen H, et al. Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. Am J Cardiol 2007; 100:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1528/abstract/48\">",
"      Roldan CA, Gill EA, Shively BK. Prevalence and diagnostic value of precordial murmurs for valvular regurgitation in obese patients treated with dexfenfluramine. Am J Cardiol 2000; 86:535.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8125 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-5849588C53-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_31_1528=[""].join("\n");
var outline_f1_31_1528=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANORECTIC DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Relation to valvular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - FDA case definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ERGOT DERIVATIVES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Migraine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MDMA (ECSTASY)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8125\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8125|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/10/21677\" title=\"figure 1\">",
"      Anorectic drugs aortic regurg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/19/318\" title=\"figure 2\">",
"      Valvular regurgitation dexfen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/27/31165\" title=\"figure 3\">",
"      Blood pressure AR with dexfen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21194?source=related_link\">",
"      Acute treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=related_link\">",
"      Cabergoline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12472?source=related_link\">",
"      Carcinoid heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=related_link\">",
"      Drug therapy of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=related_link\">",
"      Preventive treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_31_1529="Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis";
var content_f1_31_1529=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/31/1529/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/31/1529/contributors\">",
"     William M Sikov, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/31/1529/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/31/1529/contributors\">",
"     Julie R Gralow, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/31/1529/contributors\">",
"     Anees B Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/31/1529/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/31/1529/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/31/1529/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H544206541\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neoadjuvant systemic therapy is the accepted approach for women with locally advanced breast cancer for whom immediate surgery is not feasible. It is also an option for women with operable breast cancer who desire an attempt at breast conservation but in whom mastectomy is indicated based on tumor size and location [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1529/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Response assessment during and following neoadjuvant therapy, implications for surgical management of the breast and axillary nodes, pathologic evaluation of the surgical specimen, influence of pathologic findings on prognosis, and options for adjuvant therapy following neoadjuvant treatment will be reviewed here. The rationale for neoadjuvant therapy, patient selection, pre-treatment evaluation, and treatment options are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35466?source=see_link\">",
"     \"Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic options\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1192123\">",
"    <span class=\"h1\">",
"     TREATMENT EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H441568946\">",
"    <span class=\"h2\">",
"     Clinical response assessment during treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing neoadjuvant systemic therapy for breast cancer should undergo periodic clinical evaluations during treatment to assess response and ensure that their tumor is not progressing.",
"   </p>",
"   <p>",
"    There are no formal guidelines regarding the ideal assessment strategy during neoadjuvant treatment. Our approach is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients on neoadjuvant chemotherapy (NACT), we perform a clinical examination every two to four weeks (ie, prior to each cycle of treatment). This should include evaluation of the affected breast and ipsilateral axilla.",
"     </li>",
"     <li>",
"      For patients undergoing neoadjuvant endocrine therapy, we perform clinical evaluations every four to eight weeks. Their response to treatment is expected to take a longer time to become evident.",
"     </li>",
"     <li>",
"      Imaging studies (ultrasound [US] or magnetic resonance imaging [MRI]) should only be performed if disease progression is suspected based on clinical exam.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no role for repeat biopsy of the index tumor during neoadjuvant treatment unless performed as part of a clinical trial. Although repeat measurement for biologic factors (such as Ki-67) may identify patients who are unlikely to respond to neoadjuvant endocrine therapy, validation of such tests are needed before repeat pathologic assessment during treatment is incorporated into clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1529/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/28/43465?source=see_link&amp;anchor=H11#H11\">",
"     \"Measurement of prognostic factors in breast cancer\", section on 'Markers of proliferation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1192223\">",
"    <span class=\"h2\">",
"     Clinical response assessment after treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a patient has completed neoadjuvant therapy (typically six to eight cycles of chemotherapy or three to four months of endocrine therapy), assessment of tumor response helps to guide the surgical approach. Tumor size is typically assessed with the World Health Organization-International Union Against Cancer (WHO-UICC) or Response Evaluation Criteria in Solid Tumors (RECIST) criteria (",
"    <a class=\"graphic graphic_table graphicRef57181 \" href=\"UTD.htm?21/54/22380\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1529/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. However, the correlation between tumor measurements by physical examination, imaging (mammography, US or MRI), and tumor size on final pathologic analysis is modest at best [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1529/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. This is illustrated in the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2010 meta-analysis of 25 studies that involved a total of 1212 patients receiving neoadjuvant therapy concluded that while contrast-enhanced MRI has high specificity (91 percent), its sensitivity to predict pathologic complete response (pCR) was low (63 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/31/1529/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study involving 189 patients, the reported accuracy (defined as the ability to predict greatest tumor dimension within 1 cm) of clinical exam, ultrasound, and mammography were 66, 75, and 70 percent, respectively, compared to findings at final pathologic analysis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/31/1529/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The lack of concordance between clinical and pathologic assessment of response may be due to the variable patterns of tumor response to neoadjuvant treatment, which ranges from symmetric shrinkage around a central core (that may contain residual cancer or fibrotic tissue) to the complete resolution of a discrete mass despite persistence of microscopic foci of residual invasive cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H544206548\">",
"    <span class=\"h1\">",
"     DEFINITIVE SURGICAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the primary objectives of neoadjuvant therapy is to improve surgical outcomes for patients with newly diagnosed breast cancer. We recommend proceeding with definitive surgery as soon as the patient has recovered from toxicities due to neoadjuvant treatment. This typically takes three to six weeks after completing neoadjuvant chemotherapy. Of note, patients treated with endocrine therapy typically do not need to discontinue treatment prior to proceeding with surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1192512\">",
"    <span class=\"h2\">",
"     Breast surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for breast surgery after neoadjuvant therapy are similar to those used for women with newly diagnosed breast cancer who did not undergo neoadjuvant therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=see_link&amp;anchor=H12#H12\">",
"     \"Breast conserving therapy\", section on 'Role of neoadjuvant treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12586?source=see_link&amp;anchor=H1378592045#H1378592045\">",
"     \"Mastectomy\", section on 'Selection criteria for mastectomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39386?source=see_link\">",
"     \"Breast reconstruction in women with breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1192519\">",
"    <span class=\"h2\">",
"     Nodal evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who are candidates for neoadjuvant chemotherapy (NACT), our approach to evaluation of the axilla is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinically negative axillary examination (cN0) &mdash; Outside of a clinical trial, patients who are candidates for neoadjuvant chemotherapy (NACT) and have a clinically negative axillary examination at presentation (cN0) may have a sentinel lymph node biopsy (SLNB) either prior to or after neoadjuvant chemotherapy. The timing is often determined by preferences of the local treating physician, and in the absence of data suggesting a preferred strategy, either is reasonable. If the SLNB is negative (pN0), no further axillary evaluation is required.",
"     </li>",
"     <li>",
"      Clinically involved (cN1 or greater) or pathologically confirmed (pN1 or greater) axillary nodes &mdash; For patients with clinically detected or pathologically confirmed axillary node involvement",
"      <strong>",
"       prior",
"      </strong>",
"      <strong>",
"       to",
"      </strong>",
"      NACT (eg, by axillary ultrasound and fine needle aspiration or SLNB), an axillary lymph node dissection (ALND) should be performed.",
"      <br/>",
"      <br/>",
"      However, if these patients have a clinically negative axillary exam",
"      <strong>",
"       after",
"      </strong>",
"      NACT, a posttreatment SLNB can be performed in an effort to spare some patients from the morbidity associated with an ALND.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the posttreatment SLNB is negative, then an ALND may be avoided, particularly if dual tracer is used in the sentinel node procedure, at least two sentinel nodes are assessed, and removal of the previously positive node is confirmed (ie, by clip placement in the sampled lymph node).",
"     </li>",
"     <li>",
"      If the SLNB is positive, then an ALND should be offered to these patients.",
"     </li>",
"     <li>",
"      All patients should meet with a radiation oncologist to discuss the role of RT. (See",
"      <a class=\"local\" href=\"#H544206583\">",
"       'Radiation therapy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Following neoadjuvant chemotherapy, an axillary node dissection should also be performed in patients at high risk for recurrence, including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Women with multiple involved sentinel nodes (pN1 or greater)",
"     </li>",
"     <li>",
"      Women in whom adjuvant RT is not planned",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evidence to support these recommendations comes from two trials that were presented at the 2012 San Antonio Breast Cancer Conference.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the SENTinel Node Biopsy before or after NeoAdjuvant Systemic Treatment (SENTINA) trial, patients underwent nodal evaluation based on their clinical presentation [",
"      <a class=\"abstract\" href=\"UTD.htm?1/31/1529/abstract/14\">",
"       14",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Women who were cN0 at baseline underwent a pre-NACT SLNB. Those who were pN0 underwent no further surgical procedures. Women with evidence of pathologic nodal involvement",
"      <span class=\"nowrap\">",
"       (cN0/pN1)",
"      </span>",
"      underwent a repeat SLNB plus ALND following completion of neoadjuvant therapy.",
"     </li>",
"     <li>",
"      Women with cN1 disease at baseline did not undergo axillary staging prior to neoadjuvant treatment. Following completion of NACT, patients with persistent evidence of clinical node involvement at the end of neoadjuvant underwent ALND. Those patients who converted to cN0 (83 percent) at the end of NACT underwent SLNB and ALND. &nbsp;",
"     </li>",
"     <li>",
"      Among who underwent a post-neoadjuvant therapy SLNB and ALND, the detection rate of sentinel nodes",
"      <strong>",
"       after",
"      </strong>",
"      the completion of neoadjuvant treatment was significantly higher among women who presented with cN1 compared to those with",
"      <span class=\"nowrap\">",
"       cN0/pN1",
"      </span>",
"      disease at presentation (80 versus 61 percent, respectively, p&lt;0.001). The false negative rate from post-NACT SLNB was lower in the cN1 group who had not undergone pre-treatment SLNB (14 versus 52 percent for",
"      <span class=\"nowrap\">",
"       cN0/pN1).",
"      </span>",
"     </li>",
"     <li>",
"      Although this was not a randomized trial and the results cannot be directly compared across treatment arms, this study supports the decision to proceed with axillary nodal staging following completion of NACT, particularly for patients presenting with nodal involvement at initial diagnosis, regardless of whether it is detected clinically or by a pre-treatment SLNB. It also suggests that NACT may have a negative impact on the success of SLNB.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the American College of Surgeons Oncology Group (ACOSOG) trial Z1071, patients with at least cN1 disease at diagnosis (confirmed by FNA or biopsy) underwent SLNB and ALND after neoadjuvant chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/31/1529/abstract/15\">",
"       15",
"      </a>",
"      ]. The main results were as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The sentinel node detection rate was 93 percent.",
"     </li>",
"     <li>",
"      40 percent of cN1 patients had converted to pN0 after NACT. &nbsp;",
"     </li>",
"     <li>",
"      The false negative rate was 31 and 13 percent depending on whether one versus two or more sentinel nodes were examined, respectively. Given that all patients on this study had cN1 disease at diagnosis, it is likely that the true false negative rate among all women undergoing NACT will be lower.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We await final results from these two studies, including analysis of the predictive value of axillary ultrasound following NACT in patients enrolled on ACOSOG Z1071, but we may need additional studies to assess the clinical impact of false negative sentinel nodes in cN1 to cN0 patients who do not undergo ALND. Therefore, we advocate a stratified, conservative approach to nodal evaluation for patients who are candidates for neoadjuvant chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H441569430\">",
"    <span class=\"h1\">",
"     PATHOLOGIC ASSESSMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1192781\">",
"    <span class=\"h2\">",
"     Staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Joint Committee on Cancer and the International Union for Cancer Control (AJCC-UICC) TNM breast cancer staging system uses \"y\" to designate the pathologic stage after neoadjuvant therapy (ypTNM) (",
"    <a class=\"graphic graphic_table graphicRef65393 \" href=\"UTD.htm?29/14/29920\">",
"     table 2",
"    </a>",
"    ). The tumor (ypT) is measured as the largest single focus of invasive tumor, not including areas of fibrosis within the tumor bed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1192788\">",
"    <span class=\"h2\">",
"     Defining efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When interpreting the results of clinical trials evaluating neoadjuvant treatment, the clinician needs to be aware of how efficacy is defined in each study. Because this information may play a role in interpretation of response in clinical practice, the response determinations following chemotherapy and endocrine therapy are reviewed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1192795\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients treated with neoadjuvant chemotherapy (NACT), the absence of invasive disease in the breast and axilla (ypT0N0) is considered a pathologic complete response (pCR) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1529/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. However, there is controversy over the implications of a pCR on prognosis, which is discussed below. (See",
"    <a class=\"local\" href=\"#H441569536\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A lack of pCR also increases the risk of a locoregional recurrence. Other risk factors were reported from an analysis of two neoadjuvant trials conducted by the National Surgical Adjuvant Breast and Bowel Project (NSABP) (n=3000 women) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1529/abstract/18\">",
"     18",
"    </a>",
"    ]. The following were associated with a higher risk of a locoregional recurrence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age &lt;50 years (HR 0.78, 95% CI 0.63-0.98)",
"     </li>",
"     <li>",
"      Clinical tumor size &gt;5 cm at presentation (HR 1.51, 95% CI 1.19-1.91)",
"     </li>",
"     <li>",
"      Nodal involvement at presentation (HR 1.61, 95% CI 1.28-2.02)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1192802\">",
"    <span class=\"h3\">",
"     Endocrine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ER-positive breast cancers rarely achieve a pCR with neoadjuvant endocrine therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1529/abstract/19\">",
"     19",
"    </a>",
"    ]. Therefore, efficacy is usually reported as the clinical response rate or rate of breast conserving surgery on clinical trials. More recently, attempts have been made to quantitate response to neoadjuvant endocrine therapy. An example of this is the preoperative endocrine prognostic index (PEPI) score, which takes into account tumor and nodal stage, level of ER expression, and the proliferative rate (defined by the percent of cells expressing Ki67) following neoadjuvant endocrine therapy. In one study involving 158 patients, the PEPI score [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1529/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significantly predicted the risk of relapse (10 percent for PEPI score 0, 23 percent for PEPI score 1 to 3, and 48 percent for PEPI score &ge;4)",
"     </li>",
"     <li>",
"      Significantly predicted the risk of breast cancer death (2, 11, and 17 percent, respectively) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the PEPI score appears promising as a prognostic test for patients who received neoadjuvant endocrine therapy, it requires validation before it is used in routine clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1192810\">",
"    <span class=\"h2\">",
"     Re-testing of pathologic markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with residual invasive disease at surgery, we do not recommend re-testing of ER, PR and HER2 on the surgical specimen. While discordance in ER, PR, and HER2 receptors between the initial tumor biopsy and tissue obtained at surgery has been reported, it is not known whether this is a sampling effect or modulation of expression as a direct result of neoadjuvant treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1529/abstract/21\">",
"     21",
"    </a>",
"    ]. More importantly, there is no evidence that adjuvant (postoperative) treatment decisions should be influenced by the status of the receptors following neoadjuvant therapy. Thus, until data become available, we recommend basing adjuvant treatment decisions on pretreatment tumor receptor status. (See",
"    <a class=\"local\" href=\"#H1192978\">",
"     'Adjuvant therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1192978\">",
"    <span class=\"h1\">",
"     ADJUVANT THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H544206583\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients treated with neoadjuvant therapy, the indications for postoperative (adjuvant) RT are similar to those used to determine candidates for RT following primary breast conserving surgery or mastectomy. In general, we and others suggest postoperative RT for all patients treated with breast conserving surgery, for patients with locally advanced breast cancer (stage III disease) that underwent mastectomies, and for the majority of patients with histologically positive lymph nodes remaining after neoadjuvant chemotherapy (NACT) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1529/abstract/22\">",
"     22",
"    </a>",
"    ]. However, older patients with low volume lymph node involvement may not benefit from postmastectomy radiation.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41017?source=see_link\">",
"       \"Postmastectomy chest wall irradiation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11385?source=see_link\">",
"       \"Role of radiation therapy in breast conservation therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/55/42873?source=see_link\">",
"       \"Radiation techniques for locally advanced breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39657?source=see_link\">",
"       \"Techniques of breast and chest wall irradiation for early stage breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of postoperative RT for patients treated with neoadjuvant therapy has not been evaluated in prospective trials. However, since most of these patients had larger tumors or regional nodal involvement prior to neoadjuvant treatment, they are generally considered to be at increased risk of local recurrence. Retrospective studies suggest that postoperative RT improves local control even for women who have a pathologic complete response (pCR) to NACT [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1529/abstract/23-29\">",
"     23-29",
"    </a>",
"    ]. As an example, in one study of patients treated with NACT followed by mastectomy, those treated with postmastectomy RT (n=542) had a significantly lower rate of locoregional recurrence (LRR) at 10 years (22 versus 11 percent) and a lower risk of death from breast cancer (HR: 0.5; 95% CI: 0.34-0.71) than those who did not receive adjuvant RT (n=134) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1529/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, some data suggest that the response to neoadjuvant therapy can be a useful predictor of the risk for a locoregional recurrence following NACT. In a combined analysis involving over 3000 patients treated on two neoadjuvant chemotherapy trials conducted by the National Surgical Adjuvant Breast and Bowel Project (NSABP), on which patients did not receive postmastectomy or regional nodal irradiation, the following factors were associated with an increased risk for a locoregional recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1529/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tumor size before NACT &gt;5 cm (HR 1.51, 95% CI 1.19-1.91)",
"     </li>",
"     <li>",
"      Clinical node involvement before NACT (HR 1.61, 95% CI 1.28-2.02)",
"     </li>",
"     <li>",
"      Presence of residual cancer in the breast (HR 1.55, 95% CI 1.01-2.39) or the lymph nodes (HR 2.71, 95% CI 1.79-4.09) after NACT",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that it may be possible to identify a cohort of patients who would not benefit from postoperative RT due to a sufficiently low risk of a locoregional recurrence (eg, patients with a tumor &lt;5 cm and no evidence of axillary node involvement who achieve a pCR with NACT). However, these results require further validation before they can be used to inform clinical decisions. Until more data become available, we recommend basing decisions regarding the use of postoperative RT on tumor characteristics prior to neoadjuvant therapy, irrespective of clinical or pathologic response, which is consistent with guidelines from the National Comprehensive Cancer Network [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1529/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H544206590\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who received NACT, we suggest not administering adjuvant (postoperative) chemotherapy. Additional chemotherapy following surgery has not been evaluated in clinical trials and whether further chemotherapy improves overall survival to justify its toxicity is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1529/abstract/19,31,32\">",
"     19,31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, adjuvant (postoperative) chemotherapy may reasonably be offered in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients with residual triple-negative (ER, PR, and HER2-negative) breast cancer if their neoadjuvant regimen did not include both an anthracycline and a taxane. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34441?source=see_link&amp;anchor=H98882362#H98882362\">",
"       \"Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer\", section on 'Treatment approach to triple-negative breast cancer'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients treated with neoadjuvant endocrine therapy, provided they are eligible for chemotherapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37961?source=see_link&amp;anchor=H115555550#H115555550\">",
"       \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\", section on 'Indications for treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who did not complete their planned course of chemotherapy in the neoadjuvant setting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H544206597\">",
"    <span class=\"h2\">",
"     HER2-directed treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend initiation (if the patient did not receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    concurrent with all or some of their neoadjuvant chemotherapy) or resumption of trastuzumab after surgery to complete a full year of treatment rather than for shorter durations. This recommendation is based on the relapse-free and overall survival benefits seen with this extended trastuzumab treatment administered as part of adjuvant therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11384?source=see_link&amp;anchor=H517953427#H517953427\">",
"     \"Adjuvant medical therapy for HER2-positive breast cancer\", section on 'Trastuzumab-based therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H544206604\">",
"    <span class=\"h2\">",
"     Endocrine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endocrine therapy is an essential component of treatment for women with hormone-receptor positive breast cancer in both the adjuvant and metastatic settings. Following neoadjuvant therapy, we recommend that all women with hormone receptor-positive breast cancer receive adjuvant endocrine therapy following locoregional treatment. For patients with HER2-positive and hormone receptor-positive breast cancer, both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    and endocrine therapy can be started simultaneously. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although initiating (or continuing) endocrine therapy through surgery and postoperative recovery is generally not associated with additional complications, there is concern among some experts regarding concomitant delivery of radiation therapy and endocrine therapy. There are few data to inform preferred timing of endocrine therapy with RT, and this is generally based on provider and institutional practice. Therefore, while some experts begin endocrine therapy concurrently with RT, others prefer a more conservative approach and initiate endocrine therapy following RT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link&amp;anchor=H466326046#H466326046\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\", section on 'Timing of endocrine therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H441569536\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of patients with breast cancer who undergo neoadjuvant chemotherapy (NACT) is largely based upon the pathologic response found at the time of surgery, though presenting clinical stage and tumor characteristics also influence prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1529/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. As described above, clinical response is a poor predictor of pathologic response, and achieving a pathologic complete response (pCR) in the breast and axilla is a better predictor of survival than a clinical complete response (CCR) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1529/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1192781\">",
"     'Staging'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The prognostic significance of a pCR on survival endpoints has been evaluated in several meta-analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1529/abstract/33,36,37\">",
"     33,36,37",
"    </a>",
"    ]. In the largest meta-analysis performed by The Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC), 12 randomized trials comprising almost 13,000 patients were included [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1529/abstract/37\">",
"     37",
"    </a>",
"    ]. All studies had a well-delineated definition of pCR, reported on both event free (EFS) and overall survival (OS), and collected long term follow-up information. Events were defined as any locoregional or distant recurrence or death from any cause. As presented at the 2012 San Antonio Breast Cancer Symposium, the major results were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who achieved a pCR had significant improvement in EFS (HR 0.48, p&lt;0.001) and OS (HR 0.36, p&lt;0.001) compared to patients who did not. Inclusion of patients with residual ductal carcinoma in situ (DCIS) only (ypTis, ypN0) did not diminish the benefit of achieving a pCR on EFS and OS, while adding patients with residual nodal disease",
"      <span class=\"nowrap\">",
"       (ypT0/is,ypN1)",
"      </span>",
"      did.",
"     </li>",
"     <li>",
"      The pCR rate (and the probability of remaining free of an event compared to patients who did not achieve a pCR) varied by the breast cancer subtype:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hormone receptor (HR)-positive, HER2 negative, grade 1 to 2: 7 percent (HR for EFS 0.63, p=0.07)",
"     </li>",
"     <li>",
"      HR positive, HER2 negative, grade 3: 16 percent (HR 0.27, p&lt;0.001)",
"     </li>",
"     <li>",
"      HR positive, HER2 positive (treated with a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      -containing regimen): 30 percent (HR 0.58, p=0.001)",
"     </li>",
"     <li>",
"      HR negative, HER2 negative (triple-negative): 34 percent (HR 0.24, p&lt;0.001)",
"     </li>",
"     <li>",
"      HR negative, HER2 positive (treated with a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      -containing regimen): 50 percent (HR 0.25, p&lt;0.001)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the analysis concentrated on trial level data to determine the",
"    <em>",
"     magnitude",
"    </em>",
"    of the benefit of pCR needed to improve survival outcomes, there was no correlation found between pCR rates and EFS. The lack of an association might be attributed to the heterogeneous patient populations included in many of the studies, relatively low pCR rates (even in the &ldquo;superior&rdquo; treatment arm),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the lack of effective targeted agents for many of patient populations studied.",
"   </p>",
"   <p>",
"    This meta-analysis confirmed the relationship between pCR and survival outcomes for women treated with neoadjuvant chemotherapy, particularly for women with HER2 positive, triple negative, or HR-positive, grade 3 tumors. In addition, it supported the use of pathologic clearance of invasive disease in both the breast and the axillary nodes",
"    <span class=\"nowrap\">",
"     (ypT0/is,",
"    </span>",
"    ypN0) in defining pCR. However, it could not determine how large of a benefit in the pCR rate would be required to show a significant impact on long-term outcomes. How these findings might influence US FDA guidelines on the approval of agents tested in the neoadjuvant setting remains to be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1529/abstract/38\">",
"     38",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Several models are being developed to better define the prognosis of patients treated with neoadjuvant therapy. Examples of these include calculation of the",
"    <a class=\"external\" href=\"file://www3.mdanderson.org/app/medcalc/index.cfm?pagename=jsconvert3\">",
"     residual cancer burden (RCB)",
"    </a>",
"    score, the breast cancer index (BCI), and for patients treated specifically with neoadjuvant endocrine therapy, the PEPI score [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1529/abstract/20,39,40\">",
"     20,39,40",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1192802\">",
"     'Endocrine therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The RCB takes into account residual tumor size, percent of residual tumor that is comprised of invasive cancer cells (as opposed to fibrosis or in situ disease), the number of positive axillary nodes, and the largest nodal metastatic deposit [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1529/abstract/39\">",
"     39",
"    </a>",
"    ]. In the original analysis, the RCB score correlated with prognosis in patients who had received anthracycline and taxane containing NACT regimen.",
"   </p>",
"   <p>",
"    Measurement of the RCB requires collection of pathologic variables, which are not routinely recorded. In addition, validation of this prognostic index is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1529/abstract/41\">",
"     41",
"    </a>",
"    ]. Therefore, further evaluation of the RCB is required before it is used as part of routine practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/39/8818?source=see_link\">",
"       \"Patient information: Inflammatory breast cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/47/5875?source=see_link\">",
"       \"Patient information: Locally advanced and inflammatory breast cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1193835\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neoadjuvant systemic therapy refers to the administration of chemotherapy, endocrine therapy, or biologic therapy prior to surgery for breast cancer. (See",
"      <a class=\"local\" href=\"#H544206541\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35466?source=see_link&amp;anchor=H179173117#H179173117\">",
"       \"Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic options\", section on 'Treatment options'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients undergoing neoadjuvant systemic therapy, we assess response during treatment to ensure there is no evidence of disease progression. (See",
"      <a class=\"local\" href=\"#H1192123\">",
"       'Treatment evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients on neoadjuvant chemotherapy (NACT), we perform a clinical examination every two to four weeks (ie, prior to each cycle of treatment). This should include evaluation of the affected breast and ipsilateral axilla.",
"     </li>",
"     <li>",
"      For those undergoing neoadjuvant endocrine therapy, response to treatment is expected to take a longer time to become evident. As such, we perform clinical evaluations every four to eight weeks while on treatment.",
"     </li>",
"     <li>",
"      Imaging studies should only be performed if disease progression is suspected based on clinical exam",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The surgical approach following neoadjuvant treatment depends upon the pretreatment evaluation, clinical response, and patient preference. (See",
"      <a class=\"local\" href=\"#H544206548\">",
"       'Definitive surgical treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recommendations regarding adjuvant treatment depend on the pretreatment tumor characteristics, efficacy of treatment as defined at final pathology, and the neoadjuvant treatment administered. (See",
"      <a class=\"local\" href=\"#H1192978\">",
"       'Adjuvant therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We base recommendations regarding postoperative radiation therapy (RT) on the tumor characteristics prior to the start of neoadjuvant therapy. In general, we and others suggest postoperative RT for all patients treated with breast conserving surgery, for patients with locally advanced breast cancer (stage III disease) treated with mastectomy, and for the majority of patients with histologically positive lymph nodes remaining after preoperative chemotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H544206583\">",
"       'Radiation therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11385?source=see_link\">",
"       \"Role of radiation therapy in breast conservation therapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41017?source=see_link\">",
"       \"Postmastectomy chest wall irradiation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In general, we suggest not administering adjuvant chemotherapy after neoadjuvant treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H544206590\">",
"       'Chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with HER2-positive breast cancer, we recommend adjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      rather than observation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest trastuzumab for a total treatment duration of one year rather than for a shorter duration (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H544206597\">",
"       'HER2-directed treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with hormone receptor-positive breast cancer, we recommend adjuvant endocrine therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For patients with HER2-positive and hormone receptor-positive breast cancer, we initiate endocrine therapy during treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H544206604\">",
"       'Endocrine therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with breast cancer who undergo NACT, prognosis is largely based upon the pathologic response in the breast and the axilla at the time of surgery. (See",
"      <a class=\"local\" href=\"#H441569536\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with hormone receptor-positive breast cancers rarely achieve a pathologic complete response following neoadjuvant endocrine therapy. Therefore, efficacy is usually reported as the clinical response rate or rate of breast conserving surgery. (See",
"      <a class=\"local\" href=\"#H441569536\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/1\">",
"      Gralow JR, Burstein HJ, Wood W, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 2008; 26:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/2\">",
"      Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006; 24:1940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/3\">",
"      Schwartz GF, Hortobagyi GN. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. Cancer 2004; 100:2512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/4\">",
"      Shannon C, Smith I. Is there still a role for neoadjuvant therapy in breast cancer? Crit Rev Oncol Hematol 2003; 45:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/5\">",
"      Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. J Clin Oncol 2011; 29:2342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/6\">",
"      Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/7\">",
"      Hayward JL, Carbone PP, Heuson JC, et al. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer 1977; 39:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/8\">",
"      Husband JE, Schwartz LH, Spencer J, et al. Evaluation of the response to treatment of solid tumours - a consensus statement of the International Cancer Imaging Society. Br J Cancer 2004; 90:2256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/9\">",
"      Chagpar AB, Middleton LP, Sahin AA, et al. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg 2006; 243:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/10\">",
"      Fiorentino C, Berruti A, Bottini A, et al. Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease. Breast Cancer Res Treat 2001; 69:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/11\">",
"      Segara D, Krop IE, Garber JE, et al. Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol 2007; 96:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/12\">",
"      Peintinger F, Kuerer HM, Anderson K, et al. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol 2006; 13:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/13\">",
"      Yuan Y, Chen XS, Liu SY, Shen KW. Accuracy of MRI in prediction of pathologic complete remission in breast cancer after preoperative therapy: a meta-analysis. AJR Am J Roentgenol 2010; 195:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/14\">",
"      Kuehn T, Baurefiend IGP, Fehm T, et al. Sentinel lymph node biopsy before or after neoadjuvant chemotherapy- Final results from the prospective, German, multiinstitutional SENTINA trial. Cancer Res 2012; 72:95s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/15\">",
"      Boughey JC, Simon VJ, Mittendorf EA, et al. The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy- results from the ACOSOG Z1071 trial. Cancer Res 2012; 72:94s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/16\">",
"      Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/17\">",
"      Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006; 24:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/18\">",
"      Mamounas EP, Anderson SJ, Dignam JJ, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol 2012; 30:3960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/19\">",
"      Kimmick GG, Cirrincione C, Duggan DB, et al. Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944). Breast Cancer Res Treat 2009; 113:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/20\">",
"      Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008; 100:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/21\">",
"      van de Ven S, Smit VT, Dekker TJ, et al. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev 2011; 37:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/22\">",
"      Kaufmann M, Morrow M, von Minckwitz G, et al. Locoregional treatment of primary breast cancer: consensus recommendations from an International Expert Panel. Cancer 2010; 116:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/23\">",
"      Huang EH, Tucker SL, Strom EA, et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol 2004; 22:4691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/24\">",
"      Abdel-Wahab M, Wolfson A, Raub W, et al. The importance of postoperative radiation therapy in multimodality management of locally advanced breast cancer: a phase II trial of neoadjuvant MVAC, surgery, and radiation. Int J Radiat Oncol Biol Phys 1998; 40:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/25\">",
"      Buchholz TA, Tucker SL, Masullo L, et al. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol 2002; 20:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/26\">",
"      Ring A, Webb A, Ashley S, et al. Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer? J Clin Oncol 2003; 21:4540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/27\">",
"      Panades M, Olivotto IA, Speers CH, et al. Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis. J Clin Oncol 2005; 23:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/28\">",
"      McGuire SE, Gonzalez-Angulo AM, Huang EH, et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 2007; 68:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/29\">",
"      Pierce LJ, Lippman M, Ben-Baruch N, et al. The effect of systemic therapy on local-regional control in locally advanced breast cancer. Int J Radiat Oncol Biol Phys 1992; 23:949.",
"     </a>",
"    </li>",
"    <li>",
"     NCCN Guidelines Version 3.2012: Breast Cancer file://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (Accessed on September 24, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/31\">",
"      Thomas E, Holmes FA, Smith TL, et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol 2004; 22:2294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/32\">",
"      Alvarez RH, Booser DJ, Cristofanilli M, et al. Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099. Cancer 2010; 116:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/33\">",
"      von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/34\">",
"      Chen AM, Meric-Bernstam F, Hunt KK, et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol 2004; 22:2303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/35\">",
"      Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev 2007; :CD005002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/36\">",
"      Kong X, Moran MS, Zhang N, et al. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer 2011; 47:2084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/37\">",
"      Cortazar P, Zhang L, Untch M, et al. Meta-analysis results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC). Cancer Res 2012; 72:93s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/38\">",
"      Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 2012; 366:2438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/39\">",
"      Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007; 25:4414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/40\">",
"      Mathieu MC, Mazouni C, Kesty NC, et al. Breast Cancer Index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy. Ann Oncol 2012; 23:2046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1529/abstract/41\">",
"      Nahleh Z, Sivasubramaniam D, Dhaliwal S, et al. Residual cancer burden in locally advanced breast cancer: a superior tool. Curr Oncol 2008; 15:271.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14224 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-403C6C9E42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_31_1529=[""].join("\n");
var outline_f1_31_1529=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1193835\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544206541\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1192123\">",
"      TREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H441568946\">",
"      Clinical response assessment during treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1192223\">",
"      Clinical response assessment after treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H544206548\">",
"      DEFINITIVE SURGICAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1192512\">",
"      Breast surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1192519\">",
"      Nodal evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H441569430\">",
"      PATHOLOGIC ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1192781\">",
"      Staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1192788\">",
"      Defining efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1192795\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1192802\">",
"      - Endocrine therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1192810\">",
"      Re-testing of pathologic markers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1192978\">",
"      ADJUVANT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H544206583\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H544206590\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H544206597\">",
"      HER2-directed treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H544206604\">",
"      Endocrine therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H441569536\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1193835\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/14224\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/14224|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/54/22380\" title=\"table 1\">",
"      Revised RECIST criteria only",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/14/29920\" title=\"table 2\">",
"      TNM stage breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37961?source=related_link\">",
"      Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11384?source=related_link\">",
"      Adjuvant medical therapy for HER2-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=related_link\">",
"      Breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39386?source=related_link\">",
"      Breast reconstruction in women with breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34441?source=related_link\">",
"      Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12586?source=related_link\">",
"      Mastectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/28/43465?source=related_link\">",
"      Measurement of prognostic factors in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35466?source=related_link\">",
"      Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic options",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/39/8818?source=related_link\">",
"      Patient information: Inflammatory breast cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/47/5875?source=related_link\">",
"      Patient information: Locally advanced and inflammatory breast cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41017?source=related_link\">",
"      Postmastectomy chest wall irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/55/42873?source=related_link\">",
"      Radiation techniques for locally advanced breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11385?source=related_link\">",
"      Role of radiation therapy in breast conservation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39657?source=related_link\">",
"      Techniques of breast and chest wall irradiation for early stage breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_31_1530="An overview of amyloidosis";
var content_f1_31_1530=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   An overview of amyloidosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/31/1530/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/31/1530/contributors\">",
"     Peter D Gorevic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/31/1530/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/31/1530/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/31/1530/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/31/1530/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/31/1530/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although case descriptions dating back to the early 1600s probably recorded what we now recognize as amyloidosis, it was Rudolph Virchow in 1854 who adopted the term &ldquo;amyloid,&rdquo; first introduced by Schleiden in 1838 to describe plant starch, to refer to tissue deposits of material that stained in a similar manner to cellulose when exposed to iodine. In these original descriptions, amyloid deposits were noted by Rokitansky to have a &ldquo;waxy&rdquo; or &ldquo;lardaceous&rdquo; appearance grossly and by Virchow to be amorphous and hyaline on light microscopy. Congo red staining (later shown to confer typical apple",
"    <strong>",
"     -",
"    </strong>",
"    green birefringence with polarized microscopy) for the better demonstration of amyloid was introduced in the 1920s by Bennhold, and the use of thioflavine T (producing an intense yellow-green fluorescence) was popularized in the 1950s (",
"    <a class=\"graphic graphic_picture graphicRef63840 graphicRef78183 graphicRef54148 graphicRef75254 \" href=\"UTD.htm?43/14/44266\">",
"     picture 1A-D",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electron microscopic examination of amyloid deposits, first performed in 1959, generally demonstrates straight and unbranching fibrils 8 to 10 nm in width, which may be composed of protofilaments at higher resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Transmission electron and atomic force microscopy have had a role in elucidating the three dimensional structure of these macromolecular aggregates and in defining folding intermediates [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/4\">",
"     4",
"    </a>",
"    ]. In many instances, the type of amyloid fibril unit can be further defined by immunohistology (immunofluorescence or immunoenzymatic techniques) or by immunoelectron microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A general overview of the pathogenesis, clinical manifestations, diagnosis, and treatment of the different amyloid disorders is presented here. More complete discussions of the individual disorders are presented elsewhere on the appropriate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyloidosis is a generic term that refers to the extracellular tissue deposition of fibrils composed of low molecular weight subunits (most of which are in the molecular weight range of 5 to 25 kD) of a variety of proteins, many of which circulate as constituents of plasma. At least 27 different human and nine different animal protein precursors of amyloid fibrils are now known. Listings of these molecules, nomenclature for subunit proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/6\">",
"     6",
"    </a>",
"    ], and corresponding amyloid diseases are presented in the tables (",
"    <a class=\"graphic graphic_table graphicRef70058 graphicRef81283 \" href=\"UTD.htm?15/20/15694\">",
"     table 1A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42153?source=see_link\">",
"     \"Genetic factors in the amyloid diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As is apparent from these tables, several types of amyloidosis are clearly hereditary, and, in most familial forms, clinical disease has been linked to missense mutations of the precursor proteins. In some instances, deletions or premature stop codon mutations have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Virtually all of the heredofamilial amyloidoses associated with nephropathic, neuropathic, or cardiopathic disease are dominantly inherited heterozygous disorders, and both the wild-type and mutant molecules can be identified in the amyloid deposits. In some instances (eg, transthyretin [TTR], apolipoprotein A-I [ApoAI], Alzheimer amyloid precursor protein [APP], prion protein [PRP]), both the wild-type and mutant molecules may separately form amyloid fibrils under different circumstances (eg, wild type TTR, ApoA1, and Ab deposits in association with organ-specific aging pathology in the heart, aorta, and brain, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42153?source=see_link\">",
"     \"Genetic factors in the amyloid diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Amyloid fibrils are insoluble polymers comprised of low molecular weight subunit proteins. These subunits are derived in turn from soluble precursors which undergo conformational changes that lead to the adoption of a predominantly antiparallel beta-pleated sheet configuration [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/7,11\">",
"     7,11",
"    </a>",
"    ]. Oligomeric intermediates that are nonfibrillar may be responsible for tissue toxicity and disease pathogenesis in certain amyloid related disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Routes to fibrillogenesis include partial folding or unfolding of the precursor protein that may be facilitated by acidification or proteolysis and accelerated by nucleation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/13\">",
"     13",
"    </a>",
"    ]. Fibril formation is also associated with co-deposition of other nonfibrillar substances, notably including glycosaminoglycans (GAGs, particularly heparan sulfate), serum amyloid P-component (SAP, a member of the pentraxin family that includes C-reactive protein), and specific apolipoproteins (E and J) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/14\">",
"     14",
"    </a>",
"    ]. Cofactors may significantly modulate fibrillogenesis at any of several steps involved in the conversion of soluble precursors to fibrils and potentially may influence the deposition phase of amyloid in tissue, as well as resorption [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic factors may be involved in one or more ways in predisposing to the development of fibrillogenesis and amyloidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42153?source=see_link\">",
"     \"Genetic factors in the amyloid diseases\"",
"    </a>",
"    .) Heritable effects include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mutant genes encoding abnormal proteins that are more prone to fibrillogenesis than their wild-type counterparts",
"     </li>",
"     <li>",
"      Polymorphisms of cofactors (eg apolipoprotein E) or of subunit proteins (eg, serum amyloid A)",
"     </li>",
"     <li>",
"      Heritable disorders that affect the level or accumulation of precursor proteins (eg presenilin mutations in familial Alzheimer disease)",
"     </li>",
"     <li>",
"      Heritable disorders that may result in chronic inflammation and deposition of precursor protein in susceptible populations (eg, pyrin and cryopyrin mutations in Familial Mediterranean Fever [FMF] and Muckle Wells syndrome, tumor necrosis factor [TNF] receptor mutations in the TNF receptor associated periodic syndrome [TRAPS], respectively, and serum amyloid A [SAA] polymorphisms in other forms of Secondary [AA] amyloidosis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TYPES OF AMYLOIDOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, the most frequent types of amyloidosis seen on internal medicine services and tertiary referral centers are the AL (primary) and AA (secondary) types. What follows is a brief review of the major types of amyloidosis with links to more complete discussions elsewhere in UpToDate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     AL amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;AL amyloidosis is due to deposition of protein derived from immunoglobulin light chain fragments. It is a plasma cell dyscrasia in which a monoclonal immunoglobulin is detectable in the serum or monoclonal light chains in the urine in approximately 80 percent of cases.",
"   </p>",
"   <p>",
"    AL amyloidosis can occur alone or in association with multiple myeloma or, much less often, Waldenstr&ouml;m&rsquo;s macroglobulinemia or non-Hodgkin lymphoma. Light chain deposition disease has a similar pathogenesis and shares some clinical manifestations with AL amyloidosis; the primary difference is that deposited light chain fragments generally do not form fibrils and do not engender deposition of amyloid cofactors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=see_link\">",
"     \"Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=see_link&amp;anchor=H28#H28\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\", section on 'Amyloidosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H33#H33\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'AL amyloidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     AA amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;AA amyloidosis may complicate chronic diseases in which there is ongoing or recurring inflammation, such as rheumatoid arthritis (RA), spondyloarthropathy, or inflammatory bowel disease; chronic infections; or periodic fever syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/16\">",
"     16",
"    </a>",
"    ]. The fibrils are composed of fragments of the acute phase reactant serum amyloid A. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33000?source=see_link\">",
"     \"Causes and diagnosis of secondary (AA) amyloidosis and relation to rheumatic diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30086?source=see_link\">",
"     \"Pathogenesis of secondary (AA) amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Dialysis-related amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysis-related amyloidosis is due to deposition of fibrils derived from beta-2 microglobulin, which accumulate in patients with end-stage renal disease who are being maintained for prolonged periods of time by dialysis. This disorder has a predilection for osteoarticular structures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5609?source=see_link\">",
"     \"Dialysis-related amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Heritable amyloidoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many mutations lead to heritable types of amyloidosis, and the hallmark clinical features are outlined in the tables (",
"    <a class=\"graphic graphic_table graphicRef70058 graphicRef81283 \" href=\"UTD.htm?15/20/15694\">",
"     table 1A-B",
"    </a>",
"    ). An example of this heterogeneous group of disorders is heritable neuropathic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiomyopathic amyloidosis due to deposition of fibrils derived from transthyretin (also referred to as prealbumin). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42153?source=see_link\">",
"     \"Genetic factors in the amyloid diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Age-related (senile) systemic amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deposition of otherwise normal (wild-type) transthyretin in myocardium and other sites has been referred to as Systemic Senile Amyloidosis (SSA) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/17\">",
"     17",
"    </a>",
"    ]. Compared with patients with AL amyloidosis, those with the senile systemic disease survive longer (75 versus 11 months) despite having ventricular free wall and septal thickening due to amyloid deposits [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/18\">",
"     18",
"    </a>",
"    ]. Significant renal involvement is rare in the senile systemic disorder; carpal tunnel syndrome may be seen. In one study, all 18 affected patients were older men. There may be considerable overlap clinically between senile cardiac amyloidosis due to deposition of wild-type TTR, and late-onset cardiomyopathy due to mutant TTR. A family history may not be apparent, and a screen for informative mutations (notably Ile122, particularly in African Americans) may be necessary to distinguish the two causes of restrictive cardiomyopathy in older adults. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Organ-specific amyloid'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Organ-specific amyloid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyloid deposition can be isolated to a single organ, such as the skin, eye, heart, pancreas, or genitourinary tract, resulting in specific syndromes. Forms of primary localized cutaneous amyloidosis include macular, nodular, and lichen amyloidosis, with the last occurring in some families with multiple endocrine neoplasia type 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=see_link\">",
"     \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Circulating forms of the relevant subunit protein do not appear to be the precursors of the fibril in several forms of localized or organ-specific amyloidosis, in contrast with the systemic amyloids in which such circulating forms are presumed to be the precursors. In some instances (eg, localized AL amyloidosis involving the conjunctiva, lung, skin, or genitourinary tract),",
"    <strong>",
"    </strong>",
"    organ-specific amyloidosis has been shown to be identical to systemic forms of amyloid biochemically. It is presumed that the precursor protein is synthesized and processed at sites contiguous to amyloid deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/20,22\">",
"     20,22",
"    </a>",
"    ]. This model for amyloid formation at the sites of synthesis has been corroborated in some animal models of AA amyloid, in which deposition occurs around cell types such as monocytes, macrophages, or mesangial cells in tissue culture.",
"   </p>",
"   <p>",
"    The most common clinically important form of organ-specific amyloid occurs in patients with Alzheimer disease in which plaques and amyloid-laden cerebral vessels are composed of the beta protein (Ab), a 39 to 43 residue polypeptide that is cleaved out of the much larger amyloid precursor protein (APP) by secretases that are specific for its amino (beta-secretase) and carboxy (gamma-secretase) terminal residues.",
"   </p>",
"   <p>",
"    Isolated bladder amyloidosis can be the cause of life threatening hemorrhage and irritative voiding symptoms; in most instances, this appears to be a localized form immunoglobulin light chain (AL) amyloid disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of precursor protein, the tissue distribution, and the amount of amyloid deposition largely determine the clinical manifestations. In the two most common forms of systemic amyloidosis, primary (AL) and secondary (AA amyloidosis), the major sites of clinically important amyloid deposition are in the kidneys, heart, and liver. In some disorders, clinically important amyloid deposition is limited to one organ. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Types of amyloidosis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H9\">",
"     'Organ-specific amyloid'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Some clinical and laboratory features that suggest amyloidosis include waxy skin and easy bruising, enlarged muscles (eg, tongue, deltoids), symptoms and signs of heart failure, cardiac conduction abnormalities, hepatomegaly, evidence of heavy proteinuria or the nephrotic syndrome, peripheral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    autonomic neuropathy, and impaired coagulation.",
"   </p>",
"   <p>",
"    The prevalence of the most common types of amyloidosis varies in different parts of the world. In developed countries, AL is the most common type of systemic amyloidosis, while, in developing countries, AA amyloid is more frequent. This is a likely result of a higher burden of chronic infectious diseases such as tuberculosis, leprosy, and osteomyelitis in the latter [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal involvement most often presents as asymptomatic proteinuria or clinically apparent nephrotic syndrome. However, primary deposition can be limited to the blood vessels or tubules; such patients present with renal failure with little or no proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/25\">",
"     25",
"    </a>",
"    ]. End-stage renal disease is the cause of death in a minority of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/29/13784?source=see_link\">",
"     \"Renal amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac involvement can lead to systolic or diastolic dysfunction and the symptoms of heart failure. Other manifestations that can occur include syncope due to arrhythmia or heart block and angina or infarction due to accumulation of amyloid in the coronary arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Gastrointestinal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatomegaly with or without splenomegaly is a common finding in some forms of amyloidosis. Other gastrointestinal manifestations include bleeding (due to vascular fragility and loss of vasomotor responses to injury), gastroparesis, constipation, bacterial overgrowth, malabsorption, and intestinal pseudo-obstruction resulting from dysmotility [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12280?source=see_link\">",
"     \"Gastrointestinal amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Neurologic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mixed sensory and motor peripheral neuropathy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    autonomic neuropathy may occur and are prominent features in some of the heritable amyloidoses (called familial amyloidotic polyneuropathy) and in AL amyloidosis. Symptoms of numbness, paresthesia, and pain are frequently noted, as in peripheral neuropathy of many other etiologies. Compression of peripheral nerves, especially the median nerve within the carpal tunnel, can cause more localized sensory changes. Symptoms of bowel or bladder dysfunction and findings of orthostatic hypotension may be due to autonomic nervous system damage [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Central nervous system involvement is unusual in patients with the more common AL and AA amyloidoses. Amyloid deposits can lead to extensive cortical pathology and dementia in patients with sporadic or familial Alzheimer disease, while cerebral amyloid angiopathy can cause spontaneous cortical and subcortical intracranial bleeding, primarily in older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42153?source=see_link&amp;anchor=H22#H22\">",
"     \"Genetic factors in the amyloid diseases\", section on 'Presenilins and autosomal dominant early-onset AD'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37001?source=see_link\">",
"     \"Cerebral amyloid angiopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ischemic stroke may be the initial manifestation of amyloidosis. Risk factors for stroke are similar to those in the general population and include atrial fibrillation, hyperlipidemia, hypertension, and diabetes mellitus; echocardiographic evidence of myocardial or valvular involvement is often present and supports a cardioembolic source in the majority of those with ischemic stroke and biopsy proven amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Musculoskeletal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyloid infiltration of muscles may cause visible enlargement (ie, pseudohypertrophy). A large tongue (ie, macroglossia) or lateral scalloping of the tongue from impingement on the teeth is characteristic of AL amyloid. Arthropathy may be due to amyloid deposition in joints and surrounding structures. The \"shoulder pad\" sign is visible enlargement of the anterior shoulder due to fluid in the glenohumeral joint",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    amyloid infiltration of the synovial membrane and surrounding structures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11623?source=see_link\">",
"     \"Musculoskeletal manifestations of amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This type of shoulder involvement is characteristic of AL amyloid and dialysis related amyloidosis due to deposition of beta-2 microglobulin. Other musculoskeletal features of dialysis-related amyloidosis include scapulohumeral periarthritis, spondyloarthropathy, bone disease, and carpal tunnel syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5609?source=see_link\">",
"     \"Dialysis-related amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hematologic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyloidosis may be directly associated with a bleeding diathesis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. In one report of 337 patients, abnormal bleeding and abnormal coagulation tests were seen in 28 and 51 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/31\">",
"     31",
"    </a>",
"    ]. Two major mechanisms have been described: factor X deficiency due to binding on amyloid fibrils primarily in the liver and spleen, and decreased synthesis of coagulation factors in patients with advanced liver disease. However, some patients with abnormal bleeding have no abnormalities in any coagulation test [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/30\">",
"     30",
"    </a>",
"    ]. In such patients, amyloid infiltration of blood vessels may contribute to the bleeding diathesis. Bleeding due to acquired von Willebrand disease has been described in AL amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factor X deficiency results from the binding of factor X to amyloid fibrils [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. In a series of 368 consecutive patients with AL, 32 and 12 patients had factor X levels below 50 and 25 percent of normal, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/35\">",
"     35",
"    </a>",
"    ]. Bleeding was noted in 18 patients, which was more severe in the 12 patients whose factor X levels were &lt;25 percent of normal. Factor X levels improved following high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    chemotherapy and autologous hematopoietic cell transplantation in four of four patients obtaining complete remission and in one of two obtaining partial remission.",
"   </p>",
"   <p>",
"    Other hematologic manifestations are related to the degree of organ involvement. These include anemia in patients with renal failure or multiple myeloma and thrombocytopenia due to splenomegaly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary manifestations of amyloidosis include tracheobronchial infiltration, persistent pleural effusions, parenchymal nodules (amyloidomas), and, rarely, pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/38-47\">",
"     38-47",
"    </a>",
"    ]. Tracheobronchial infiltration can cause hoarseness, stridor, airway obstruction, and dysphagia; bronchoscopic or surgical resection of airway abnormalities may be required [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/48-53\">",
"     48-53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link\">",
"     \"Diagnosis and management of central airway obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Persistent pleural effusions develop in 1 to 2 percent of patients with systemic amyloidosis and appear to be caused by pleural infiltration with amyloid deposits [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/40,54\">",
"     40,54",
"    </a>",
"    ]. However, it is difficult to distinguish primary effusions from those caused by amyloid-induced cardiomyopathy on the basis of echocardiographic findings alone, and the sensitivity of pleural biopsy in this setting has not been studied extensively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/40\">",
"     40",
"    </a>",
"    ]. Persistent pleural effusions are associated with a poor prognosis and limited response to treatment, although pleurodesis has been useful in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/40\">",
"     40",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    in others [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/29/37334?source=see_link\">",
"     \"Management of refractory nonmalignant pleural effusions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Skin manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs of skin involvement in systemic amyloidosis include waxy thickening, easy bruising (ecchymoses), and subcutaneous nodules or plaques. Purpura, characteristically elicited in a periorbital distribution (raccoon eyes) by a valsalva maneuver or minor trauma, is present in only a minority of patients but is highly characteristic of AL amyloidosis (",
"    <a class=\"graphic graphic_picture graphicRef51684 \" href=\"UTD.htm?10/46/10979\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Amyloidosis limited to the skin may also occur. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Organ-specific amyloid'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Infiltration of the subcutaneous fat is generally asymptomatic but provides a convenient site for biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other manifestations can occur, including visual and hearing loss in some heritable amyloidoses, in addition to gross hematuria and irritative urinary symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Ischemic symptoms and tissue infarction due to vascular infiltration have also been reported. Additional manifestations include jaw claudication suggestive of giant cell (temporal) arteritis, which can occur in AL amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/57\">",
"     57",
"    </a>",
"    ], and symptomatic ischemic coronary heart disease, which is associated with the presence of obstructive intramural deposits of AL amyloid [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of amyloidosis can be confirmed only by tissue biopsy, although the presence of amyloidosis may be suggested by the history and clinical manifestations (eg, nephrotic syndrome in a patient with multiple myeloma or long-standing, active rheumatoid arthritis). Biopsies may be directed to dysfunctional organs (eg. kidney, nerve) or to clinically uninvolved sites such as subcutaneous fat, minor salivary glands, or rectal mucosa.",
"   </p>",
"   <p>",
"    We suggest a fat pad aspiration as the initial biopsy technique for patients with other than single organ involvement, because fat pad aspiration biopsy is less likely than liver, renal, or even rectal biopsy to be complicated by serious bleeding. Aspiration biopsy of subcutaneous fat with Congo red staining and examination using polarizing microscopy has a sensitivity of 57 to 85 percent and a specificity of 92 to 100 percent for AL or AA amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/59-62\">",
"     59-62",
"    </a>",
"    ]. Fat pad aspiration biopsy has a low sensitivity for amyloidosis in patients with a single involved organ. The diagnostic sensitivity is higher in those with multiorgan involvement who are suspected of having systemic amyloidosis due to immunoglobulin light chain (primary, or AL), AA protein (secondary), or transthyretin (senile cardiac or familial amyloid polyneuropathy) deposition. (See",
"    <a class=\"local\" href=\"#H23769855\">",
"     'Abdominal fat pad biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Biopsy of a specifically involved site is suggested for patients with a limited number of affected organs, because patients with single organ involvement are less likely to have biopsies of unaffected tissues reveal amyloid. This was illustrated by a study of 450 patients with peripheral neuropathy who had fat pad aspiration biopsies performed; among the 143 who had only peripheral neuropathy, none had amyloid deposits noted in the aspiration biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/63\">",
"     63",
"    </a>",
"    ]. In contrast, among the 307 patients with at least one other clinical feature of amyloidosis, the rate of positive aspirations was 6 percent.",
"   </p>",
"   <p>",
"    The sensitivity of rectal biopsy in one large series composed predominantly of patients with systemic amyloid (\"primary amyloid\" and myeloma associated in 193 patients, \"secondary\" or localized to a single organ in 41 patients) was 84 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/64\">",
"     64",
"    </a>",
"    ]. The sensitivity of kidney, liver, and carpal-tunnel biopsies were all 90 percent or more in this cohort.",
"   </p>",
"   <p>",
"    Some patients have a predisposing underlying disorder before the presentation with amyloid, while others present with no such history but with an amyloid manifestation such as otherwise unexplained heart failure or nephrotic syndrome. In such patients, the diagnosis of amyloidosis comes first, followed by an evaluation for a cause (eg, plasma cell dyscrasia for AL, chronic inflammatory disease for AA).",
"   </p>",
"   <p>",
"    Tissue biopsy is important because assumptions regarding the type of amyloid may be incorrect. As an example, AA amyloidosis is only one cause of the nephrotic syndrome in patients with rheumatoid arthritis; other causes include drug side-effects, immune-complex disease, or an unrelated disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37812?source=see_link\">",
"     \"Renal disease in patients with rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some noninvasive tests can provide supportive but not definitive findings. Examples include a speckled appearance of the myocardium on echocardiography, lytic bone lesions in multiple myeloma, and cystic bone lesions in dialysis-related amyloidosis.",
"   </p>",
"   <p>",
"    Although liver biopsy is rarely complicated by life-threatening bleeding, less invasive approaches to diagnosis than percutaneous liver biopsy are generally preferred. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/58/29608?source=see_link&amp;anchor=H13#H13\">",
"     \"Percutaneous, fine-needle aspiration, and laparoscopic liver biopsy\", section on 'Amyloid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The amyloid deposits appear as amorphous hyaline material on light microscopy (",
"    <a class=\"graphic graphic_picture graphicRef63840 graphicRef78183 graphicRef54148 graphicRef75254 \" href=\"UTD.htm?43/14/44266\">",
"     picture 1A-D",
"    </a>",
"    ). The fibrils bind Congo red (leading to green birefringence under polarized light) and thioflavine T (producing an intense yellow-green fluorescence). On electron microscopy, they are 8 to 10 nm in width and are straight and unbranching [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some cases, immunohistology can be used to identify the type of protein subunit [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. This is most useful for AA and TTR amyloid and is less so for AL amyloid; variable staining of AL deposits with standard antisera to kappa or lambda constant region-determinants is due to loss of antigenic epitopes in the course of proteolytic processing of the constant region that precedes fibrillogenesis. Variable region-specific antibodies to immunoglobulin light chain subclass determinants may provide an approach to circumventing this limitation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7418?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Direct determination of the proteins present in the amyloid deposits, either by amino acid sequencing or mass spectroscopy, is the most straightforward approach to characterizing the type of amyloid present in the biopsy specimen. These direct methods of protein analysis are applicable to formalin-fixed paraffin-embedded biopsy specimens. However, these analyses are available only at specialized centers. The validation of this methodology for commercial purposes has been of particular interest. This method is performed using laser capture microdissection of amyloid from formalin-fixed amyloidotic tissue, followed by trypsin digestion, mass spectroscopy, and direct sequence analysis of peptides [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/68\">",
"     68",
"    </a>",
"    ]. This methodology, which was originally used for the analysis of the proteomics of AL amyloid, has also been validated for AA, specific tissues, including nerve in patients with amyloid neuropathy, and abdominal fat pad aspirates [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23769855\">",
"    <span class=\"h3\">",
"     Abdominal fat pad biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sampling of subcutaneous tissue was introduced in the 1970s as a diagnostic technique for some systemic forms of amyloidosis and remains a valuable tool, either as an aspiration of the abdominal fat pad or as a deep biopsy of the subcutaneous fat performed by a dermatologist or surgeon [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/70\">",
"     70",
"    </a>",
"    ]. Initial studies involved fine needle aspiration, which has subsequently been used in some studies in combination with ultrastructural and immunohistologic analysis of tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A protocol has been utilized in clinical studies which involves repeated aspirations carried out at sites about 10 cm lateral to the umbilicus using 10 mL syringes with negative pressure through a 16-guage needle. This procedure is simple and can be performed in the office over 20 to 30 minutes, but the critical steps for analysis are proper preparation of glass slides for microscopic analysis by congo red birefringence and for immunohistology, which should be carried out by a pathology laboratory that is experienced with appropriate antibodies and which regularly carries out controls to validate testing. The aim of repeated aspiration, which may be done on both sides of the umbilicus as necessary, is to obtain adequate fat (approximately 30 mg) for routine studies, which may be increased to incorporate quantitation of subunit proteins by methods such as enzyme-linked immunoassay [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/72\">",
"     72",
"    </a>",
"    ]",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proteomic studies (mass spectroscopy, two dimensional gel electrophoresis, protein sequence analysis). By contrast, skin biopsy has the potential to distinguish patterns of deposition in the various systemic amyloids [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/73\">",
"     73",
"    </a>",
"    ] and to enhance isolation by laser capture microdissection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     SAP scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scintigraphy with radioisotope labeled serum amyloid P component (SAP) can identify the distribution of amyloid, and provide an estimate of the total body burden of fibrillar deposits [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/74\">",
"     74",
"    </a>",
"    ]. Sensitivity of SAP scanning of 90 percent for AA and AL amyloid is contrasted with 48 percent for hereditary ATTR amyloidosis; the specificity is 93 percent in all three conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/75\">",
"     75",
"    </a>",
"    ]. However, the value of SAP scintigraphy is limited because it is currently obtained from blood donors (thereby carrying a potential infectious risk) and is less helpful in detecting cardiac amyloid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7418?source=see_link&amp;anchor=H1666860#H1666860\">",
"     \"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)\", section on 'Serum amyloid P component scintigraphy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Paraproteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;AL amyloidosis should be suspected in all patients with amyloid deposits who do not have a chronic infectious or inflammatory disease, end-stage renal disease, or a family history of amyloidosis. Patients who have biopsy-documented amyloidosis and meet criteria for a well-defined plasma cell dyscrasia, such as multiple myeloma or Waldenstr&ouml;m&rsquo;s macroglobulinemia, need not undergo further diagnostic testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=see_link\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7418?source=see_link&amp;anchor=H1665099#H1665099\">",
"     \"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)\", section on 'Evidence of monoclonal plasma cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients without a history of plasma cell dyscrasia, initial testing is aimed at determining whether a monoclonal population of plasma cells is present. This is usually accomplished by testing for a monoclonal protein by serum and urine protein electrophoresis (",
"    <a class=\"graphic graphic_figure graphicRef67685 \" href=\"UTD.htm?21/3/21566\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef55073 \" href=\"UTD.htm?7/20/7503\">",
"     figure 2",
"    </a>",
"    ) and immunofixation (",
"    <a class=\"graphic graphic_figure graphicRef55916 \" href=\"UTD.htm?4/39/4735\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef75044 \" href=\"UTD.htm?42/51/43824\">",
"     figure 4",
"    </a>",
"    ). Quantitation of serum free light chains has been utilized as an adjunctive diagnostic modality that may demonstrate clonality in patients with AL amyloid who do not have monoclonal proteins by immunofixation; this assay may also be used to follow response to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link&amp;anchor=H2212928#H2212928\">",
"     \"Recognition of monoclonal proteins\", section on 'Serum free light chains'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bone marrow biopsy can confirm the diagnosis of plasma cell dyscrasia by demonstrating a monoclonal population of plasma cells (",
"    <a class=\"graphic graphic_picture graphicRef79371 \" href=\"UTD.htm?16/38/16998\">",
"     picture 3",
"    </a>",
"    ). Biopsies should be specifically stained for amyloid, and immunohistology and flow cytometry should be performed with antibodies to kappa and lambda light chains to look for clonality of plasma cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Bone marrow examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the presence of a monoclonal protein alone is not sufficient to make a diagnosis of AL amyloid in a patient with documented amyloidosis unless immunofluorescence has demonstrated monoclonal light chains in the amyloid deposits [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. The potential for misdiagnosis based upon a serum or urine monoclonal protein alone was illustrated in a study of 350 patients suspected of having AL amyloidosis by clinical and laboratory findings and the absence of a family history [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/78\">",
"     78",
"    </a>",
"    ]. Ten percent of these patients had a mutant gene for an \"amyloidogenic\" protein, most often involving the alpha-chain of fibrinogen A or transthyretin. In 8 of these 34 patients, the presence of low concentrations of monoclonal immunoglobulins (all less than 0.2",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    contributed to the misdiagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42153?source=see_link\">",
"     \"Genetic factors in the amyloid diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A thorough family history and exclusion of these heritable disorders are warranted if a plasma cell dyscrasia cannot be documented [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. Treatment programs utilized for AL amyloidosis (eg, chemotherapy, hematopoietic cell transplantation) have no role in patients with hereditary forms of amyloidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of the different types of amyloidosis varies with the cause of fibril production. As examples, therapy is aimed at the underlying infectious or inflammatory disorder in AA amyloidosis, at the underlying plasma cell dyscrasia in AL amyloidosis, and at either altering the mode of dialysis or considering renal transplantation in patients with dialysis-related amyloidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23383?source=see_link\">",
"     \"Treatment of secondary (AA) amyloidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35994?source=see_link\">",
"     \"Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5609?source=see_link\">",
"     \"Dialysis-related amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the hereditary amyloidoses in which the mutant amyloid precursor protein is produced by the liver (eg, transthyretin, apolipoprotein A-I, and fibrinogen Aa), liver transplantation may in some instances prevent further deposition of amyloid and may lead to regression of established deposits [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. Transplantation during the first year after appearance of symptoms is ideal. Patients with sporadic or undiagnosed hereditary amyloidosis who present with advanced end-organ damage may benefit from combined hepatorenal or hepatocardiac transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/81-83\">",
"     81-83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23958?source=see_link&amp;anchor=H16788234#H16788234\">",
"     \"Treatment of amyloid cardiomyopathy\", section on 'Specific therapy of TTR amyloidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Novel approaches to treatment are being investigated. Agents that interfere with fibril formation, prevent the formation of amyloidogenic precursors, hasten degradation of existing amyloid deposits, or disrupt the interaction between amyloidogenic proteins and accessory molecules, such as SAP and heparitin sulfate proteoglycans, have been shown to be effective in animal models, and some have progressed to human trials [",
"    <a class=\"abstract\" href=\"UTD.htm?1/31/1530/abstract/84,85\">",
"     84,85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42792546\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Amyloidosis is a generic term that refers to the extracellular tissue deposition of fibrils composed of low molecular weight subunits of a variety of proteins, many of which circulate as constituents of plasma. These subunit proteins are derived, in turn, from soluble precursors which undergo conformational changes that lead to the adoption of a predominantly antiparallel beta-pleated sheet configuration. At least 27 different human protein precursors of amyloid fibrils are known (",
"      <a class=\"graphic graphic_table graphicRef70058 graphicRef81283 \" href=\"UTD.htm?15/20/15694\">",
"       table 1A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The two major forms of amyloidosis are the AL (primary) and AA (secondary) types. AL amyloid, the most common form in developed countries, is due to deposition of protein derived from immunoglobulin light chain fragments. It is a plasma cell dyscrasia in which a monoclonal immunoglobulin is detectable in the serum or monoclonal light chains in the urine in approximately 80 percent of cases. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'AL amyloidosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      AA amyloidosis, the most common form in developing countries, may complicate chronic diseases in which there is ongoing or recurring inflammation, such as chronic infections; rheumatoid arthritis (RA), spondyloarthropathy, or inflammatory bowel disease; or periodic fever syndromes. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'AA amyloidosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Other major forms seen clinically include dialysis-related amyloidosis, heritable amyloidoses, age-related systemic amyloidosis and organ-specific amyloid. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Dialysis-related amyloidosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Heritable amyloidoses'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Age-related (senile) systemic amyloidosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Organ-specific amyloid'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations vary depending upon the type of amyloid and the distribution of deposition. Some clinical and laboratory features that suggest amyloidosis include waxy skin and easy bruising, enlarged muscles (eg, tongue, deltoids), symptoms and signs of heart failure, cardiac conduction abnormalities, hepatomegaly, evidence of heavy proteinuria or the nephrotic syndrome, peripheral",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      autonomic neuropathy, and impaired coagulation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Types of amyloidosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tissue biopsy should be used to confirm the diagnosis in all cases of amyloidosis, although the diagnosis of amyloidosis may be suspected on the basis of history and clinical manifestations. Fat pad aspiration biopsy is less likely than liver, renal, or even rectal biopsy to be complicated by serious bleeding; we thus suggest it as the initial biopsy technique for patients with other than single organ involvement. In patients with single organ involvement, biopsy of the clinically involved site is suggested because fat pad aspiration biopsy has a low sensitivity for amyloidosis in such patients. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who have biopsy-documented amyloidosis and meet criteria for a well-defined plasma cell dyscrasia, such as multiple myeloma or Waldenstr&ouml;m&rsquo;s macroglobulinemia, need not undergo further diagnostic testing. Patients who are not known to have a plasma cell disorder should be further tested to determine whether a monoclonal protein is present in serum, urine, or both. A combination of serum and urine protein electrophoresis, followed by immunofixation, is recommended. Quantitation of serum free light chains is suggested for AL patients who do not have monoclonal proteins by immunofixation. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Paraproteins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of a monoclonal protein alone is not sufficient to make a diagnosis of AL amyloid in a patient with documented amyloidosis unless immunofluorescence has demonstrated monoclonal light chains in the amyloid deposits. Heritable types of amyloidosis should be excluded if a plasma cell dyscrasia (multiple myeloma or Waldenstr&ouml;m&rsquo;s macroglobulinemia) cannot be documented. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Paraproteins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of the different types of amyloidosis varies with the cause of fibril production. As examples, therapy is aimed at the underlying infectious or inflammatory disorder in AA amyloidosis, at the underlying plasma cell dyscrasia in AL amyloidosis, and at either altering the mode of dialysis or considering renal transplantation in patients with dialysis-related amyloidosis. Liver transplantation may be effective in certain of the hereditary amyloidoses. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/1\">",
"      Kyle RA. Amyloidosis: a convoluted story. Br J Haematol 2001; 114:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/2\">",
"      COHEN AS, CALKINS E. Electron microscopic observations on a fibrous component in amyloid of diverse origins. Nature 1959; 183:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/3\">",
"      Stromer T, Serpell LC. Structure and morphology of the Alzheimer's amyloid fibril. Microsc Res Tech 2005; 67:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/4\">",
"      Gosal WS, Myers SL, Radford SE, Thomson NH. Amyloid under the atomic force microscope. Protein Pept Lett 2006; 13:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/5\">",
"      Picken MM. Amyloidosis-where are we now and where are we heading? Arch Pathol Lab Med 2010; 134:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/6\">",
"      Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid 2010; 17:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/7\">",
"      Bellotti V, Nuvolone M, Giorgetti S, et al. The workings of the amyloid diseases. Ann Med 2007; 39:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/8\">",
"      Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007; 36:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/9\">",
"      Mucchiano GI, H&auml;ggqvist B, Sletten K, Westermark P. Apolipoprotein A-1-derived amyloid in atherosclerotic plaques of the human aorta. J Pathol 2001; 193:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/10\">",
"      Yazaki M, Liepnieks JJ, Kincaid JC, Benson MD. Contribution of wild-type transthyretin to hereditary peripheral nerve amyloid. Muscle Nerve 2003; 28:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/11\">",
"      Jahn TR, Radford SE. Folding versus aggregation: polypeptide conformations on competing pathways. Arch Biochem Biophys 2008; 469:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/12\">",
"      Lindgren M, Hammarstr&ouml;m P. Amyloid oligomers: spectroscopic characterization of amyloidogenic protein states. FEBS J 2010; 277:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/13\">",
"      Rochet JC, Lansbury PT Jr. Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol 2000; 10:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/14\">",
"      Kisilevsky R. The relation of proteoglycans, serum amyloid P and apo E to amyloidosis current status, 2000. Amyloid 2000; 7:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/15\">",
"      Dergunov AD. Role of ApoE in conformation-prone diseases and atherosclerosis. Biochemistry (Mosc) 2006; 71:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/16\">",
"      Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356:2361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/17\">",
"      Westermark P, Bergstr&ouml;m J, Solomon A, et al. Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations. Amyloid 2003; 10 Suppl 1:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/18\">",
"      Ng B, Connors LH, Davidoff R, et al. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 2005; 165:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/19\">",
"      Tanaka A, Arita K, Lai-Cheong JE, et al. New insight into mechanisms of pruritus from molecular studies on familial primary localized cutaneous amyloidosis. Br J Dermatol 2009; 161:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/20\">",
"      Meijer JM, Schonland SO, Palladini G, et al. Sj&ouml;gren's syndrome and localized nodular cutaneous amyloidosis: coincidence or a distinct clinical entity? Arthritis Rheum 2008; 58:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/21\">",
"      Baykal C, Buyukbabani N, Boztepe H, et al. Multiple cutaneous neuromas and macular amyloidosis associated with medullary thyroid carcinoma. J Am Acad Dermatol 2007; 56:S33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/22\">",
"      Hamidi Asl K, Liepnieks JJ, Nakamura M, Benson MD. Organ-specific (localized) synthesis of Ig light chain amyloid. J Immunol 1999; 162:5556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/23\">",
"      Monge M, Chauveau D, Cordonnier C, et al. Localized amyloidosis of the genitourinary tract: report of 5 new cases and review of the literature. Medicine (Baltimore) 2011; 90:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/24\">",
"      Westermark P, Westermark GT. Review. Reflections on amyloidosis in Papua New Guinea. Philos Trans R Soc Lond B Biol Sci 2008; 363:3701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/25\">",
"      Nishi S, Alchi B, Imai N, Gejyo F. New advances in renal amyloidosis. Clin Exp Nephrol 2008; 12:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/26\">",
"      Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart 2011; 97:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/27\">",
"      Sattianayagam P, Hawkins P, Gillmore J. Amyloid and the GI tract. Expert Rev Gastroenterol Hepatol 2009; 3:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/28\">",
"      Revesz T, Holton JL, Lashley T, et al. Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuropathol 2009; 118:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/29\">",
"      Zubkov AY, Rabinstein AA, Dispenzieri A, Wijdicks EF. Primary systemic amyloidosis with ischemic stroke as a presenting complication. Neurology 2007; 69:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/30\">",
"      Yood RA, Skinner M, Rubinow A, et al. Bleeding manifestations in 100 patients with amyloidosis. JAMA 1983; 249:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/31\">",
"      Mumford AD, O'Donnell J, Gillmore JD, et al. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol 2000; 110:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/32\">",
"      Sucker C, Hetzel GR, Grabensee B, et al. Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy. Am J Kidney Dis 2006; 47:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/33\">",
"      Kos CA, Ward JE, Malek K, et al. Association of acquired von Willebrand syndrome with AL amyloidosis. Am J Hematol 2007; 82:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/34\">",
"      Furie B, Greene E, Furie BC. Syndrome of acquired factor X deficiency and systemic amyloidosis in vivo studies of the metabolic fate of factor X. N Engl J Med 1977; 297:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/35\">",
"      Choufani EB, Sanchorawala V, Ernst T, et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood 2001; 97:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/36\">",
"      Boggio L, Green D. Recombinant human factor VIIa in the management of amyloid-associated factor X deficiency. Br J Haematol 2001; 112:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/37\">",
"      Thompson CA, Kyle R, Gertz M, et al. Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients. Am J Hematol 2010; 85:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/38\">",
"      Ross P Jr, Magro CM. Clonal light chain restricted primary intrapulmonary nodular amyloidosis. Ann Thorac Surg 2005; 80:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/39\">",
"      Howard ME, Ireton J, Daniels F, et al. Pulmonary presentations of amyloidosis. Respirology 2001; 6:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/40\">",
"      Berk JL, Keane J, Seldin DC, et al. Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis. Chest 2003; 124:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/41\">",
"      Maeno T, Sando Y, Tsukagoshi M, et al. Pleural amyloidosis in a patient with intractable pleural effusion and multiple myeloma. Respirology 2000; 5:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/42\">",
"      Ikeda S, Takabayashi Y, Maejima Y, et al. Nodular lung disease with five year survival and unilateral pleural effusion in AL amyloidosis. Amyloid 1999; 6:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/43\">",
"      Utz JP, Swensen SJ, Gertz MA. Pulmonary amyloidosis. The Mayo Clinic experience from 1980 to 1993. Ann Intern Med 1996; 124:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/44\">",
"      Dingli D, Utz JP, Gertz MA. Pulmonary hypertension in patients with amyloidosis. Chest 2001; 120:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/45\">",
"      Onozato ML, Tojo A, Ogura S, et al. Primary amyloidosis with multiple pulmonary nodular lesions and IgA nephropathy-like renal involvement. Clin Nephrol 2003; 60:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/46\">",
"      Fujimoto N, Masuoka H, Kosaka H, et al. Primary amyloidosis with pulmonary involvement which presented exudative pleural effusion and high fever. Intern Med 2003; 42:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/47\">",
"      BoydKing A, Sharma O, Stevenson K. Localized interstitial pulmonary amyloid: a case report and review of the literature. Curr Opin Pulm Med 2009; 15:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/48\">",
"      Dahl KA, Kernstine KH, Vannatta TL, et al. Tracheobronchial amyloidosis: a surgical disease with long-term consequences. J Thorac Cardiovasc Surg 2004; 128:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/49\">",
"      O'Regan A, Fenlon HM, Beamis JF Jr, et al. Tracheobronchial amyloidosis. The Boston University experience from 1984 to 1999. Medicine (Baltimore) 2000; 79:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/50\">",
"      Capizzi SA, Betancourt E, Prakash UB. Tracheobronchial amyloidosis. Mayo Clin Proc 2000; 75:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/51\">",
"      Pribitkin E, Friedman O, O'Hara B, et al. Amyloidosis of the upper aerodigestive tract. Laryngoscope 2003; 113:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/52\">",
"      Monroe AT, Walia R, Zlotecki RA, Jantz MA. Tracheobronchial amyloidosis: a case report of successful treatment with external beam radiation therapy. Chest 2004; 125:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/53\">",
"      Dedo HH, Izdebski K. Laryngeal amyloidosis in 10 patients. Laryngoscope 2004; 114:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/54\">",
"      Berk JL. Pleural effusions in systemic amyloidosis. Curr Opin Pulm Med 2005; 11:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/55\">",
"      Hoyer RJ, Leung N, Witzig TE, Lacy MQ. Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis. Am J Hematol 2007; 82:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/56\">",
"      Eder L, Bitterman H. Image in clinical medicine. Amyloid purpura. N Engl J Med 2007; 356:2406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/57\">",
"      Gertz MA, Kyle RA, Griffing WL, Hunder GG. Jaw claudication in primary systemic amyloidosis. Medicine (Baltimore) 1986; 65:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/58\">",
"      Neben-Wittich MA, Wittich CM, Mueller PS, et al. Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primary amyloidosis. Am J Med 2005; 118:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/59\">",
"      Duston MA, Skinner M, Meenan RF, Cohen AS. Sensitivity, specificity, and predictive value of abdominal fat aspiration for the diagnosis of amyloidosis. Arthritis Rheum 1989; 32:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/60\">",
"      Westermark P, Davey E, Lindbom K, Enqvist S. Subcutaneous fat tissue for diagnosis and studies of systemic amyloidosis. Acta Histochem 2006; 108:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/61\">",
"      van Gameren II, Hazenberg BP, Bijzet J, van Rijswijk MH. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum 2006; 54:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/62\">",
"      Dhingra S, Krishnani N, Kumari N, Pandey R. Evaluation of abdominal fat pad aspiration cytology and grading for detection in systemic amyloidosis. Acta Cytol 2007; 51:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/63\">",
"      Andrews TR, Colon-Otero G, Calamia KT, et al. Utility of subcutaneous fat aspiration for diagnosing amyloidosis in patients with isolated peripheral neuropathy. Mayo Clin Proc 2002; 77:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/64\">",
"      Kyle RA, Bayrd ED. Amyloidosis: review of 236 cases. Medicine (Baltimore) 1975; 54:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/65\">",
"      Arbustini E, Morbini P, Verga L, Merlini G. Light and electron microscopy immunohistochemical characterization of amyloid deposits. Amyloid 1997; 4:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/66\">",
"      Sch&ouml;nland SO, Hegenbart U, Bochtler T, et al. Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood 2012; 119:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/67\">",
"      Davern S, Tang LX, Williams TK, et al. Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies. Am J Clin Pathol 2008; 130:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/68\">",
"      Vrana JA, Gamez JD, Madden BJ, et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009; 114:4957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/69\">",
"      Klein CJ, Vrana JA, Theis JD, et al. Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue. Arch Neurol 2011; 68:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/70\">",
"      Westermark P. Amyloid diagnosis, subcutaneous adipose tissue, immunohistochemistry and mass spectrometry. Amyloid 2011; 18:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/71\">",
"      Devata S, Hari P, Markelova N, et al. Detection of amyloid in abdominal fat pad aspirates in early amyloidosis: Role of electron microscopy and Congo red stained cell block sections. Cytojournal 2011; 8:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/72\">",
"      Hazenberg BP, Limburg PC, Bijzet J, van Rijswijk MH. A quantitative method for detecting deposits of amyloid A protein in aspirated fat tissue of patients with arthritis. Ann Rheum Dis 1999; 58:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/73\">",
"      Ikeda S, Sekijima Y, Tojo K, Koyama J. Diagnostic value of abdominal wall fat pad biopsy in senile systemic amyloidosis. Amyloid 2011; 18:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/74\">",
"      Hawkins PN. Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens 2002; 11:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/75\">",
"      Hazenberg BP, van Rijswijk MH, Piers DA, et al. Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med 2006; 119:355.e15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/76\">",
"      Kumar S, Dispenzieri A, Katzmann JA, et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood 2010; 116:5126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/77\">",
"      Comenzo RL, Zhou P, Fleisher M, et al. Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood 2006; 107:3489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/78\">",
"      Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002; 346:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/79\">",
"      Saraiva MJ. Sporadic cases of hereditary systemic amyloidosis. N Engl J Med 2002; 346:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/80\">",
"      Herlenius G, Wilczek HE, Larsson M, et al. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation 2004; 77:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/81\">",
"      Yamamoto S, Wilczek HE, Nowak G, et al. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant 2007; 7:2597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/82\">",
"      Tsuchiya A, Yazaki M, Kametani F, et al. Marked regression of abdominal fat amyloid in patients with familial amyloid polyneuropathy during long-term follow-up after liver transplantation. Liver Transpl 2008; 14:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/83\">",
"      Raichlin E, Daly RC, Rosen CB, et al. Combined heart and liver transplantation: a single-center experience. Transplantation 2009; 88:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/84\">",
"      Kolstoe SE, Wood SP. Drug targets for amyloidosis. Biochem Soc Trans 2010; 38:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/31/1530/abstract/85\">",
"      Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 2011; 29:1924.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5589 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-3C09538E6E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_31_1530=[""].join("\n");
var outline_f1_31_1530=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H42792546\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TYPES OF AMYLOIDOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      AL amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      AA amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Dialysis-related amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Heritable amyloidoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Age-related (senile) systemic amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Organ-specific amyloid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Neurologic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Musculoskeletal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hematologic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Skin manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23769855\">",
"      - Abdominal fat pad biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SAP scanning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Paraproteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42792546\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5589\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5589|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/3/21566\" title=\"figure 1\">",
"      Monoclonal pattern on SPEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/20/7503\" title=\"figure 2\">",
"      Bence Jones protein UPEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/39/4735\" title=\"figure 3\">",
"      Monoclonal pattern immunofixation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/51/43824\" title=\"figure 4\">",
"      Bence Jones protein immunofix",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5589|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/25/33177\" title=\"picture 1A\">",
"      Amyloid light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/17/38162\" title=\"picture 1B\">",
"      Congo red amyloid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/58/22441\" title=\"picture 1C\">",
"      Amyloid EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/29/36306\" title=\"picture 1D\">",
"      Amyloid AA IF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/46/10979\" title=\"picture 2\">",
"      Periorbital amyloid purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/38/16998\" title=\"picture 3\">",
"      Primary amyloid bone marrow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5589|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/1/4125\" title=\"table 1A\">",
"      Amyloid precursor proteins I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/9/10397\" title=\"table 1B\">",
"      Amyloid precursor proteins II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33000?source=related_link\">",
"      Causes and diagnosis of secondary (AA) amyloidosis and relation to rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37001?source=related_link\">",
"      Cerebral amyloid angiopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=related_link\">",
"      Clinical manifestations and diagnosis of amyloid cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=related_link\">",
"      Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7418?source=related_link\">",
"      Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5609?source=related_link\">",
"      Dialysis-related amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/47/762?source=related_link\">",
"      Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12280?source=related_link\">",
"      Gastrointestinal amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42153?source=related_link\">",
"      Genetic factors in the amyloid diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/29/37334?source=related_link\">",
"      Management of refractory nonmalignant pleural effusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11623?source=related_link\">",
"      Musculoskeletal manifestations of amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=related_link\">",
"      Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30086?source=related_link\">",
"      Pathogenesis of secondary (AA) amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/58/29608?source=related_link\">",
"      Percutaneous, fine-needle aspiration, and laparoscopic liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35994?source=related_link\">",
"      Prognosis and treatment of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=related_link\">",
"      Recognition of monoclonal proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/29/13784?source=related_link\">",
"      Renal amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37812?source=related_link\">",
"      Renal disease in patients with rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23958?source=related_link\">",
"      Treatment of amyloid cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23383?source=related_link\">",
"      Treatment of secondary (AA) amyloidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_31_1531="Diagnostic studies RMS";
var content_f1_31_1531=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F73916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F73916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic studies at the time of initial presentation of rhabdomyosarcoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        CT scan of primary tumor area",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MRI of primary tumor area (parameningeal, head &amp;neck)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thin-cut (5 mm section) CT scan of abdomen (evaluation of lymph nodes with paratesticular tumors)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone scan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CT scan of chest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ultrasound (pelvic tumors)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bilateral bone marrow aspirate and biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lumbar puncture (parameningeal primary)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_31_1531=[""].join("\n");
var outline_f1_31_1531=null;
var title_f1_31_1532="Pneumatosis symptoms";
var content_f1_31_1532=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Symptoms of small and large bowel pneumatosis intestinalis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Small Intestine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1. Vomiting",
"      </td>",
"      <td>",
"       60",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       2. Abdominal distention",
"      </td>",
"      <td>",
"       59",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       3. Weight loss",
"      </td>",
"      <td>",
"       55",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       4. Abdominal discomfort",
"      </td>",
"      <td>",
"       53",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       5. Diarrhea",
"      </td>",
"      <td>",
"       27",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       6. Anorexia",
"      </td>",
"      <td>",
"       14",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       7. Constipation",
"      </td>",
"      <td>",
"       12",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Large Intestine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1. Diarrhea",
"      </td>",
"      <td>",
"       56",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       2. Hematochezia",
"      </td>",
"      <td>",
"       50",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       3. Abdominal discomfort",
"      </td>",
"      <td>",
"       32",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       4. Abdominal distention",
"      </td>",
"      <td>",
"       28",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       5. Constipation",
"      </td>",
"      <td>",
"       26",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       6. Weight loss",
"      </td>",
"      <td>",
"       16",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       7. Tenesmus",
"      </td>",
"      <td>",
"       10",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Jamart J, Acta Hepato Gastroenterol 1979; 26:419.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_31_1532=[""].join("\n");
var outline_f1_31_1532=null;
var title_f1_31_1533="Incubation period for rash I";
var content_f1_31_1533=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Incubation period for infectious diseases associated with fever and rash",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent/disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incubation period",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arcanobacterium haemolyticum",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atypical measles",
"       </td>",
"       <td>",
"        7-14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blastomyces dermatitidis",
"       </td>",
"       <td>",
"        30-45 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Boutonneuse fever (Rickettsia conorii)",
"       </td>",
"       <td>",
"        6-10 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cat scratch disease",
"       </td>",
"       <td>",
"        7-14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chancroid",
"       </td>",
"       <td>",
"        1-35 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chickenpox",
"       </td>",
"       <td>",
"        10-20 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlamydia psittaci",
"       </td>",
"       <td>",
"        5-21 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coccidioides immitis",
"       </td>",
"       <td>",
"        7-21 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coxsackie/echovirus",
"       </td>",
"       <td>",
"        2-9 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cutaneous larva migrans",
"       </td>",
"       <td>",
"        2-4 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dengue",
"       </td>",
"       <td>",
"        3-14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disseminated gonococcal infection",
"       </td>",
"       <td>",
"        5 days - several months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ehrlichiosis",
"       </td>",
"       <td>",
"        7-21 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Escherichia coli 0157:H7",
"       </td>",
"       <td>",
"        3-8 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epstein-Barr virus (mononucleosis)",
"       </td>",
"       <td>",
"        30-50 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gnathostomiasis",
"       </td>",
"       <td>",
"        3-12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granuloma inguinale",
"       </td>",
"       <td>",
"        8-80 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis B",
"       </td>",
"       <td>",
"        45-160 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis C",
"       </td>",
"       <td>",
"        14-180 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Herpes simplex (genital)",
"       </td>",
"       <td>",
"        2-7 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Human immunodeficiency virus (HIV)",
"       </td>",
"       <td>",
"        28-180 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kawasaki syndrome",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leishmaniasis",
"       </td>",
"       <td>",
"        14-56 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loiasis",
"       </td>",
"       <td>",
"        6-12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lyme disease",
"       </td>",
"       <td>",
"        3-30 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphogranuloma venerum (LGV)",
"       </td>",
"       <td>",
"        3-21 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycobacterium leprae",
"       </td>",
"       <td>",
"        &gt;1 year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycobacterium marinum",
"       </td>",
"       <td>",
"        14-56 days",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from Sanders, CV. Diagnosis of the patient with fever and rash. In: The Skin and Infection: A Color Atlas and Text, Sanders, CV, Nesbitt, LT (Eds), Williams &amp; Wilkins, Baltimore, 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_31_1533=[""].join("\n");
var outline_f1_31_1533=null;
var title_f1_31_1534="Immunomodulatory agents pulmonary diseases";
var content_f1_31_1534=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pulmonary diseases associated with immunomodulatory agents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Complications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"33\">",
"        <strong>",
"         TNF-alpha inhibitors",
"        </strong>",
"       </td>",
"       <td rowspan=\"10\">",
"        <strong>",
"         Etanercept",
"        </strong>",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Infectious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Streptococcus pneumoniae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Histoplasmosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Non-infectious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Systemic lupus erythematosus pleural disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pulmonary fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Granulomatous inflammation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pneumonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Exacerbation of interstitial disease",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"19\">",
"        <strong>",
"         Infliximab",
"        </strong>",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Infectious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bovine tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cryptococcosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Histoplasmosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Legionellosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Invasive and allergic aspergillosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Scedosporium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Actinomycosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pneumocystis jirovecii",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coccidioidomycosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Non-infectious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Langerhans cell histiocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug-induced alveolitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Systemic lupus erythematosus pleural or parenchymal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Interstitial pneumonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diffuse alveolar hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fibrosing alveolitis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        <strong>",
"         Adalimumab",
"        </strong>",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Infectious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aspergillosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pulmonary fibrosis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         IL-1 inhibitor",
"        </strong>",
"       </td>",
"       <td rowspan=\"2\">",
"        <strong>",
"         Anakinra",
"        </strong>",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Infectious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tuberculosis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Costimulation blockade",
"        </strong>",
"       </td>",
"       <td rowspan=\"2\">",
"        <strong>",
"         Abatacept",
"        </strong>",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Infectious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bacterial pneumonia",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        <strong>",
"         B cell depletion",
"        </strong>",
"       </td>",
"       <td rowspan=\"3\">",
"        <strong>",
"         Rituximab",
"        </strong>",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Non-infectious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Interstitial pneumonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pulmonary fibrosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    TNF-alpha: Tumor necrosis factor-alpha; IL-1: Interleukin-1",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Wood, KL, Hage, CA, Knox, KS, et al. Histoplasmosis after treatment with anti-tumor necrosis factor alpha therapy. Am J Respir Crit Care Med 2003; 167:1279.",
"       </li>",
"       <li>",
"        Abunasser, J, Forouhar, FA, Metersky, ML. Etanercept-induced lupus erythematosis presenting as a unilateral pleural effusion. Chest 2008; 134:850.",
"       </li>",
"       <li>",
"        Judson, MA. Allergic bronchopulmonary aspergillosis after infliximab therapy for sarcoidosis: a potential mechanism related to T-helper cell cytokine balance. Chest 2009; 135:1358.",
"       </li>",
"       <li>",
"        Larsen, MV, Sorensen, IJ, Thomsen, VO, Ravn, P. Re-activation of bovine tuberculosis in a patient treated with infliximab. Eur Respir J 2008; 32:229.",
"       </li>",
"       <li>",
"        Dweik, M, Baethge, BA, Duarte, AG. Coccidioidomycosis pneumonia in a nonendemic area associated with infliximab. South Med J 2007; 100:517.",
"       </li>",
"       <li>",
"        O'Shea, FD, Marras, TK, Inman, RD. Pulmonary sarcoidosis developing during infliximab therapy. Arthritis Rheum 2006; 55:978.",
"       </li>",
"       <li>",
"        Villeneuve, E, St-Pierre, A, Haraoui, B. Interstitial pneumonitis associated with infliximab therapy. J Rheumatol 2006; 33:1189.",
"       </li>",
"       <li>",
"        Hage, CA, Wood, KL, Winer-Muram, HT, et al. Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. Chest 2003; 124:2395.",
"       </li>",
"       <li>",
"        De Rosa, FG, Shaz, D, Campagna, AC, et al. Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case? Infect Control Hosp Epidemiol 2003; 24:477.",
"       </li>",
"       <li>",
"        Allanore, Y, Devos, Francosis, G, Caramella, C, et al. Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab. Ann Rheum Dis 2006; 65:834.",
"       </li>",
"       <li>",
"        Bitzan, M, Anselmo, M, Carpineta, L. Rituximab (B-cell depleting antibody) associated with lung injury (RALI): a pediatric case and systematic review of the literature. Pediatr Pulmonal 2009; 44:922.",
"       </li>",
"       <li>",
"        Wagner, SA, Mehta, AC, Laber, DA. Rituximab-induced interstitial lung disease. Am J Hematol 2007; 82:916.",
"       </li>",
"       <li>",
"        Biehn, SE, Kirk, D, Rivera, MP, et al. Bronchioltis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkins lymphoma. Hematol Oncol 2006; 24:234.",
"       </li>",
"       <li>",
"        Kuru, T, Lynch, LP, 3rd. Nonresolving or slowly resolving pneumonia. Clin Chest Med 1999; 20:623.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_31_1534=[""].join("\n");
var outline_f1_31_1534=null;
var title_f1_31_1535="Classification criteria for SLE";
var content_f1_31_1535=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F86633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F86633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification criteria for systemic lupus erythematosus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"10%\">",
"     </colgroup>",
"     <colgroup width=\"40%\">",
"     </colgroup>",
"     <colgroup width=\"10%\">",
"     </colgroup>",
"     <colgroup width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        ACR criteria for the classification of systemic lupus erythematosus",
"        <sup>",
"         [1,2]",
"        </sup>",
"        <br/>",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        SLICC criteria for the classification of systemic lupus erythematosus",
"        <sup>",
"         [3]",
"        </sup>",
"        <br/>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\" colspan=\"2\">",
"        (4 of 11 criteria)*",
"       </td>",
"       <td class=\"centered\" colspan=\"2\">",
"        <p>",
"         (4 of 17 criteria, including at least one clinical criterion and one immunologic criterion;",
"         <sup>",
"          &bull;",
"         </sup>",
"         <strong>",
"          OR",
"         </strong>",
"         biopsy-proven lupus nephritis",
"         <sup>",
"          &Delta;",
"         </sup>",
"         )",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2\">",
"        Criterion",
"       </td>",
"       <td class=\"subtitle2\">",
"        Definition",
"       </td>",
"       <td class=\"subtitle2\">",
"        Criterion",
"       </td>",
"       <td class=\"subtitle2\">",
"        Definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Clinical criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Malar rash",
"       </td>",
"       <td>",
"        Fixed erythema, flat or raised, over the malar eminences, tending to spare the nasolabial folds",
"       </td>",
"       <td rowspan=\"2\">",
"        Acute cutaneous lupus",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Lupus malar rash (do not count if malar discoid); bullous lupus; toxic epidermal necrolysis variant of SLE; maculopapular lupus rash; photosensitive lupus rash (in the absence of dermatomyositis);",
"         <strong>",
"          OR",
"         </strong>",
"         subacute cutaneous lupus (nonindurated psoriaform and/or annular polycyclic lesions that resolve without scarring, although occasionally with postinflammatory dyspigmentation or telangiectasias)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\">",
"        Photosensitivity",
"       </td>",
"       <td>",
"        Skin rash as a result of unusual reaction to sunlight, by patient history or physician observation",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\">",
"        Discoid rash",
"       </td>",
"       <td>",
"        Erythematosus raised patches with adherent keratotic scaling and follicular plugging; atrophic scarring may occur in older lesions",
"       </td>",
"       <td>",
"        Chronic cutaneous lupus",
"       </td>",
"       <td>",
"        <p>",
"         Classic discoid rash; localized (above the neck); generalized (above and below the neck); hypertrophic (verrucous) lupus; lupus panniculitis (profundus); mucosal lupus; lupus erythematosus tumidus; chilblains lupus;",
"         <strong>",
"          OR",
"         </strong>",
"         discoid lupus/lichen planus overlap",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Nonscarring alopecia",
"       </td>",
"       <td>",
"        Diffuse thinning or hair fragility with visible broken hairs (in the absence of other causes such as alopecia areata, drugs, iron deficiency, and androgenic alopecia)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\">",
"        Oral ulcers",
"       </td>",
"       <td>",
"        Oral or nasopharyngeal ulceration, usually painless, observed by a physician",
"       </td>",
"       <td>",
"        Oral or nasal ulcers",
"       </td>",
"       <td>",
"        <p>",
"         Palate, buccal, tongue,",
"         <strong>",
"          OR",
"         </strong>",
"         nasal ulcers (in the absence of other causes, such as vasculitis, Beh&ccedil;et's disease, infection (herpesvirus), inflammatory bowel disease, reactive arthritis, and acidic foods)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Arthritis",
"       </td>",
"       <td rowspan=\"2\">",
"        Nonerosive arthritis involving 2 or more peripheral joints, characterized by tenderness, swelling, or effusion",
"       </td>",
"       <td rowspan=\"2\">",
"        Joint disease",
"       </td>",
"       <td>",
"        Synovitis involving 2 or more joints, characterized by swelling or effusion",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tenderness in 2 or more joints and at least 30 minutes of morning stiffness",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Serositis",
"       </td>",
"       <td>",
"        Pleuritis - convincing history of pleuritic pain or rubbing heard by a physician or evidence of pleural effusion",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"       <td rowspan=\"2\">",
"        Serositis",
"       </td>",
"       <td>",
"        Typical pleurisy for more than 1 day, pleural effusions, or pleural rub,",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pericarditis - documented by EKG, rub, or evidence of pericardial effusion",
"       </td>",
"       <td>",
"        Typical pericardial pain (pain with recumbency improved by sitting forward) for more than 1 day, pericardial effusion, pericardial rub, or pericarditis by electrocardiography in the absence of other causes, such as infection, uremia, and Dressler's syndrome",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Renal disorder",
"       </td>",
"       <td>",
"        Persistent proteinuria greater than 500 mg/24 hours or greater than 3+ if quantitation not performed",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"       <td rowspan=\"2\">",
"        Renal",
"       </td>",
"       <td>",
"        Urine protein-to-creatinine ratio (or 24-hour urine protein) representing 500 mg protein/24 hours,",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cellular casts - may be red cell, hemoglobin, granular, tubular, or mixed",
"       </td>",
"       <td>",
"        Red blood cell casts",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\">",
"        Neurologic disorder",
"       </td>",
"       <td>",
"        <p>",
"         Seizures",
"         <strong>",
"          OR",
"         </strong>",
"         psychosis - in the absence of offending drugs or known metabolic derangements (uremia, ketoacidosis, or electrolyte imbalance)",
"        </p>",
"       </td>",
"       <td>",
"        Neurologic",
"       </td>",
"       <td>",
"        <p>",
"         Seizures; psychosis; mononeuritis multiplex (in the absence of other known causes such as primary vasculitis); myelitis; peripheral or cranial neuropathy (in the absence of other known causes such as primary vasculitis, infection, and diabetes mellitus);",
"         <strong>",
"          OR",
"         </strong>",
"         acute confusional state (in the absence of other causes, including toxic/metabolic, uremia, drugs)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"4\">",
"        Hematologic disorder",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         Hemolytic anemia - with reticulocytosis",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Leukopenia - less than 4000/mm",
"         <sup>",
"          3",
"         </sup>",
"         total on two or more occasions",
"         <strong>",
"          <strong>",
"           OR",
"          </strong>",
"         </strong>",
"        </p>",
"        <p>",
"         Lymphopenia - less than 1500/mm",
"         <sup>",
"          3",
"         </sup>",
"         on two or more occasions",
"         <strong>",
"          <strong>",
"           OR",
"          </strong>",
"         </strong>",
"        </p>",
"        Thrombocytopenia - less than 100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        (in the absence of offending drugs)",
"       </td>",
"       <td>",
"        Hemolytic anemia",
"       </td>",
"       <td>",
"        Hemolytic anemia",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Leukopenia or lymphopenia",
"       </td>",
"       <td>",
"        <p>",
"         Leukopenia (&lt;4000/mm",
"         <sup>",
"          3",
"         </sup>",
"         at least once) (in the absence of other known causes such as Felty's syndrome, drugs, and portal hypertension),",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphopenia (&lt;1000/mm",
"        <sup>",
"         3",
"        </sup>",
"        at least once) (in the absence of other known causes such as corticosteroids, drugs, and infection)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Thrombocytopenia",
"       </td>",
"       <td>",
"        Thrombocytopenia (&lt;100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        ) at least once in the absence of other known causes such as drugs, portal hypertension, and thrombotic thrombocytopenic purpura",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Immunologic criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        ANA",
"       </td>",
"       <td>",
"        An abnormal titer of antinuclear antibody by immunofluorescence or an equivalent assay at any point in time and in the absence of drugs known to be associated with \"drug-induced lupus\" syndrome",
"       </td>",
"       <td>",
"        ANA",
"       </td>",
"       <td>",
"        ANA level above laboratory reference range",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Immunologic disorders",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         Anti-DNA - antibody to native DNA in abnormal titer",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Anti-Sm - presence of antibody to Sm nuclear antigen",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        Positive finding of antiphospholipid antibody based on an abnormal serum level of IgG or IgM anticardiolipin antibodies, on a positive test result for lupus anticoagulant using a standard method, or on a false positive serologic test for syphilis known to be positive for at least six months and confirmed by Treponema pallidum immobilization or fluorescent treponemal antibody absorption test",
"       </td>",
"       <td>",
"        Anti-dsDNA",
"       </td>",
"       <td>",
"        Anti-dsDNA antibody level above laboratory reference range (or &gt;twofold the reference range if tested by ELISA)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Anti-Sm",
"       </td>",
"       <td>",
"        Presence of antibody to Sm nuclear antigen",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Antiphospholipid",
"       </td>",
"       <td>",
"        Antiphospholipid antibody positivity as determined by any of the following: positive test result for lupus anticoagulant; false-positive test result for rapid plasma reagin; medium- or high-titer anticardiolipin antibody level (IgA, IgG, or IgM); or positive test result for anti-&beta;2-glycoprotein I (IgA, IgG, or IgM)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Low complement",
"       </td>",
"       <td>",
"        <p>",
"         Low C3; low C4;",
"         <strong>",
"          OR",
"         </strong>",
"         low CH50",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Direct Coombs' test",
"       </td>",
"       <td>",
"        <p>",
"         Direct Coombs' test in the absence of hemolytic anemia",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ACR: American College of Rheumatology; SLICC: Systemic Lupus International Collaborating Clinics; SLE: systemic lupus erythematosus; EKG: electrocardiogram; ANA: antinuclear antibodies; anti-dsDNA: anti-double-stranded DNA; ELISA: enzyme-linked immunosorbent assay; Anti-Sm: anti-Smith antibody; IgA: immunoglobulin A.",
"     <br/>",
"     * For the ACR criteria, no distinction is made between clinical and immunologic criteria in determining whether the required number has been met. The classification is based upon 11 criteria. For the purpose of identifying patients in clinical studies, a person is said to have systemic lupus erythematosus if any 4 or more of the 11 criteria are present, serially or simultaneously, during any interval of observation.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     For the SLICC criteria, criteria are cumulative and need not be presently concurrently. A patient is classified as having SLE if he or she satisfies four of the clinical and immunologic criteria used in the SLICC classification criteria, including at least one clinical criterion and one immunologic criterion.",
"     <br/>",
"     &Delta; Alternatively, according to the SLICC criteria, a patient is classified as having SLE if he or she has biopsy-proven nephritis compatible with SLE in the presence of ANAs or anti-dsDNA antibodies.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271.",
"      </li>",
"      <li>",
"       Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus (letter). Arthritis Rheum 1997; 40:1725.",
"      </li>",
"      <li>",
"       Petri M, Orbai AM, Alarc&oacute;n GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64:2677.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_31_1535=[""].join("\n");
var outline_f1_31_1535=null;
